A	O
novel	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
Elf-1	B-protein
,	O
binds	O
to	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
regulatory	I-DNA
elements	I-DNA
that	O
are	O
required	O
for	O
inducible	O
trans	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O

Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human-peripheral-blood	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV-2	O
infection	O
may	O
be	O
more	O
prolonged	O
than	O
that	O
of	O
HIV-1	O
.	O

The	O
latent	O
phases	O
of	O
both	O
HIV-1	O
and	O
HIV-2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T-cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O

In	O
the	O
case	O
of	O
HIV-1	O
,	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
is	O
sufficient	O
for	O
inducible	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
,	O
factors	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	I-protein
are	O
required	O
to	O
activate	O
HIV-2	O
transcription	O
in	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
Elf-1	B-protein
,	O
binds	O
specifically	O
to	O
two	B-DNA
purine-rich	I-DNA
motifs	I-DNA
in	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
.	O

Mutagenesis	O
experiments	O
demonstrated	O
that	O
these	O
Elf-1	B-DNA
binding	I-DNA
sites	I-DNA
are	O
required	O
for	O
induction	O
of	O
HIV-2	O
transcription	O
following	O
T-cell-receptor-mediated	O
T-cell	O
activation	O
.	O

Moreover	O
,	O
Elf-1	B-protein
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T-cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Thus	O
,	O
Elf-1	B-protein
is	O
a	O
novel	B-protein
transcription	I-protein
factor	I-protein
that	O
appears	O
to	O
be	O
required	O
for	O
the	O
T-cell-receptor-mediated	O
trans	O
activation	O
of	O
HIV-2	O
gene	O
expression	O
.	O

These	O
results	O
may	O
explain	O
differences	O
in	O
the	O
clinical	O
spectra	O
of	O
diseases	O
caused	O
by	O
HIV-1	O
and	O
HIV-2	O
and	O
may	O
also	O
have	O
implications	O
for	O
the	O
design	O
of	O
therapeutic	O
approaches	O
to	O
HIV-2	O
infection	O
.	O

JournaL	NULL
or	NULL
ViroroGgy	NULL
,	NULL
Oct.	NULL
1992	NULL
,	NULL
p.	NULL
5890-5897	NULL
0022-538	NULL
X	NULL
,	NULL
/92/105890-08	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1992	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

66	NULL
,	NULL
No	NULL
.	NULL

10	NULL
A	NULL
Novel	NULL
Ets-Related	NULL
Transcription	NULL
Factor	NULL
,	NULL
Elf-1	NULL
,	NULL
Binds	NULL
to	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
2	NULL
Regulatory	NULL
Elements	NULL
That	NULL
Are	NULL
Required	NULL
for	NULL
Inducible	NULL
trans	NULL
Activation	NULL
in	NULL
T	NULL
Cells	NULL
JEFFREY	NULL
M.	NULL
LEIDEN	NULL
,	NULL
***+*	NULL
CHUNG-YIH	NULL
WANG	NULL
,	NULL
``	NULL
BRONISLAWA	NULL
PETRYNIAK	NULL
,	NULL
*	NULL
>	NULL
DAVID	NULL
M.	NULL
MARKOVITZ	NULL
,	NULL
``	NULL
GARY	NULL
J.	NULL
NABEL	NULL
,	NULL
***	NULL
anp	NULL
CRAIG	NULL
B.	NULL
THOMPSON®**	NULL
The	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
and	NULL
The	NULL
Departments	NULL
of	NULL
Internal	NULL
Medicine	NULL
,	NULL
``	NULL
and	NULL
Biochemistry	NULL
,	NULL
``	NULL
University	NULL
of	NULL
Michigan	NULL
Medical	NULL
Center	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
Michigan	NULL
48109-0650	NULL
Received	NULL
9	NULL
April	NULL
1992/Accepted	NULL
24	NULL
June	NULL
1992	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
and	NULL
HIV-2	NULL
are	NULL
structurally	NULL
related	NULL
retroviruses	NULL
which	NULL
both	NULL
cause	NULL
AIDS	NULL
in	NULL
humans	NULL
.	NULL

Although	NULL
both	NULL
viruses	NULL
establish	NULL
latency	NULL
in	NULL
quiescent	NULL
human-peripheral-blood	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
asymptomatic	NULL
phase	NULL
of	NULL
HIV-2	NULL
infection	NULL
may	NULL
be	NULL
more	NULL
prolonged	NULL
than	NULL
that	NULL
of	NULL
HIV-1	NULL
.	NULL

The	NULL
latent	NULL
phases	NULL
of	NULL
both	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
infection	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
disrupted	NULL
by	NULL
T-cell	NULL
activation	NULL
,	NULL
a	NULL
process	NULL
that	NULL
requires	NULL
host	NULL
cell	NULL
transcription	NULL
factors	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
HIV-1	NULL
,	NULL
the	NULL
transcription	NULL
factor	NULL
NF-xB	NULL
is	NULL
sufficient	NULL
for	NULL
inducible	NULL
transcriptional	NULL
activation	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
factors	NULL
in	NULL
addition	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
are	NULL
required	NULL
to	NULL
activate	NULL
HIV-2	NULL
transcription	NULL
in	NULL
infected	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
a	NULL
novel	NULL
Ets-related	NULL
transcription	NULL
factor	NULL
,	NULL
Elf-1	NULL
,	NULL
binds	NULL
specifically	NULL
to	NULL
two	NULL
purine-rich	NULL
motifs	NULL
in	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

Mutagenesis	NULL
experiments	NULL
demonstrated	NULL
that	NULL
these	NULL
Elf-1	NULL
binding	NULL
sites	NULL
are	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
HIV-2	NULL
transcription	NULL
following	NULL
T-cell-receptor-mediated	NULL
T-cell	NULL
activation	NULL
.	NULL

Moreover	NULL
,	NULL
Elf-1	NULL
is	NULL
the	NULL
only	NULL
factor	NULL
present	NULL
in	NULL
activated	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
that	NULL
binds	NULL
to	NULL
these	NULL
sites	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

Thus	NULL
,	NULL
Elf-1	NULL
is	NULL
a	NULL
novel	NULL
transcription	NULL
factor	NULL
that	NULL
appears	NULL
to	NULL
be	NULL
required	NULL
for	NULL
the	NULL
T-cell-receptor-mediated	NULL
frans	NULL
activation	NULL
of	NULL
HIV-2	NULL
gene	NULL
expression	NULL
.	NULL

These	NULL
results	NULL
may	NULL
explain	NULL
differences	NULL
in	NULL
the	NULL
clinical	NULL
spectra	NULL
of	NULL
diseases	NULL
caused	NULL
by	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
and	NULL
may	NULL
also	NULL
have	NULL
implications	NULL
for	NULL
the	NULL
design	NULL
of	NULL
therapeutic	NULL
approaches	NULL
to	NULL
HIV-2	NULL
infection	NULL
.	NULL

Many	NULL
RNA	NULL
and	NULL
DNA	NULL
viruses	NULL
that	NULL
infect	NULL
animal	NULL
cells	NULL
utilize	NULL
host	NULL
cell	NULL
transcription	NULL
factors	NULL
to	NULL
express	NULL
genetic	NULL
information	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
for	NULL
example	NULL
,	NULL
transcription	NULL
of	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
genome	NULL
is	NULL
regulated	NULL
by	NULL
interactions	NULL
between	NULL
several	NULL
host	NULL
cell	NULL
transcription	NULL
factors	NULL
,	NULL
including	NULL
Sp1	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
TEF-1	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
transcription	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
enhancer	NULL
appears	NULL
to	NULL
be	NULL
controlled	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
by	NULL
interactions	NULL
between	NULL
cellular	NULL
transcription	NULL
factors	NULL
that	NULL
belong	NULL
to	NULL
the	NULL
Ets	NULL
and	NULL
CREB/ATF	NULL
families	NULL
(	NULL
6	NULL
,	NULL
29	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
host	NULL
cell	NULL
transcription	NULL
factors	NULL
also	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
regulating	NULL
the	NULL
inducible	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
(	NULL
HIVs	NULL
)	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
1-3	NULL
,	NULL
17	NULL
,	NULL
25	NULL
,	NULL
30	NULL
,	NULL
31	NULL
,	NULL
36	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Two	NULL
different	NULL
types	NULL
of	NULL
HIVs	NULL
,	NULL
HIV	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
and	NULL
HIV-2	NULL
,	NULL
have	NULL
thus	NULL
far	NULL
been	NULL
described	NULL
(	NULL
4	NULL
,	NULL
8-10	NULL
,	NULL
17	NULL
,	NULL
19	NULL
,	NULL
23	NULL
,	NULL
25	NULL
,	NULL
31	NULL
)	NULL
.	NULL

The	NULL
life	NULL
cycles	NULL
of	NULL
both	NULL
viruses	NULL
are	NULL
characterized	NULL
by	NULL
an	NULL
initial	NULL
viremia	NULL
and	NULL
infection	NULL
of	NULL
circulating	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
followed	NULL
by	NULL
a	NULL
latent	NULL
relatively	NULL
asymptomatic	NULL
phase	NULL
which	NULL
can	NULL
last	NULL
for	NULL
as	NULL
long	NULL
as	NULL
10	NULL
years	NULL
and	NULL
which	NULL
is	NULL
characterized	NULL
by	NULL
a	NULL
lack	NULL
of	NULL
transcription	NULL
of	NULL
the	NULL
integrated	NULL
proviral	NULL
genome	NULL
(	NULL
11	NULL
,	NULL
17	NULL
,	NULL
25	NULL
,	NULL
31	NULL
)	NULL
.	NULL

HIV	NULL
latency	NULL
is	NULL
disrupted	NULL
by	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
during	NULL
the	NULL
process	NULL
of	NULL
T-cell-receptor	NULL
(	NULL
TCR	NULL
)	NULL
-mediated	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
proviral	NULL
genome	NULL
requires	NULL
the	NULL
participation	NULL
of	NULL
inducible	NULL
.	NULL

host	NULL
cell	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
viral	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
and	NULL
activate	NULL
viral	NULL
gene	NULL
expression	NULL
(	NULL
1-3	NULL
,	NULL
17	NULL
,	NULL
25	NULL
,	NULL
30	NULL
,	NULL
31	NULL
,	NULL
36	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
significant	NULL
differences	NULL
in	NULL
the	NULL
patterns	NULL
of	NULL
T-cell	NULL
latency	NULL
during	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
infections	NULL
(	NULL
4	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

t	NULL
Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
MC6080	NULL
,	NULL
BRH	NULL
,	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
5841	NULL
S.	NULL
Maryland	NULL
,	NULL
Chicago	NULL
,	NULL
IL	NULL
60637	NULL
.	NULL

5890	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
there	NULL
may	NULL
be	NULL
fundamental	NULL
differences	NULL
in	NULL
the	NULL
host	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
trans	NULL
activation	NULL
of	NULL
these	NULL
two	NULL
related	NULL
human	NULL
retroviruses	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
inducible	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
to	NULL
two	NULL
sites	NULL
in	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
appears	NULL
to	NULL
be	NULL
sufficient	NULL
to	NULL
activate	NULL
HIV-1	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
36	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
factors	NULL
in	NULL
addition	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
are	NULL
needed	NULL
to	NULL
activate	NULL
transcription	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
the	NULL
studies	NULL
described	NULL
in	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
two	NULL
purine-rich	NULL
sequences	NULL
(	NULL
purine	NULL
boxes	NULL
1	NULL
and	NULL
2	NULL
[	NULL
PuB1	NULL
and	NULL
PuB2	NULL
]	NULL
)	NULL
in	NULL
the	NULL
HIV-2	NULL
LTR	NULL
that	NULL
are	NULL
required	NULL
for	NULL
transcriptional	NULL
induction	NULL
following	NULL
TCR-mediated	NULL
T-cell	NULL
activation	NULL
.	NULL

We	NULL
have	NULL
also	NULL
shown	NULL
that	NULL
these	NULL
sequences	NULL
bind	NULL
a	NULL
novel	NULL
member	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
called	NULL
Elf-1	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
utilizing	NULL
an	NULL
antiserum	NULL
were	NULL
used	NULL
to	NULL
demonstrate	NULL
that	NULL
Elf-1	NULL
is	NULL
the	NULL
only	NULL
factor	NULL
in	NULL
activated	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
that	NULL
binds	NULL
to	NULL
these	NULL
purine-rich	NULL
sequence	NULL
motifs	NULL
in	NULL
EMSAs	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
show	NULL
that	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
,	NULL
unlike	NULL
that	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
,	NULL
requires	NULL
at	NULL
least	NULL
two	NULL
host	NULL
cell	NULL
transcription	NULL
factors	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Elf-1	NULL
.	NULL

These	NULL
findings	NULL
may	NULL
be	NULL
relevant	NULL
to	NULL
understanding	NULL
some	NULL
of	NULL
the	NULL
differences	NULL
in	NULL
the	NULL
biological	NULL
behavior	NULL
of	NULL
these	NULL
two	NULL
related	NULL
retroviral	NULL
pathogens	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
and	NULL
cell	NULL
lines	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
by	NULL
using	NULL
density	NULL
gradient	NULL
centrifugation	NULL
of	NULL
buffy	NULL
coats	NULL
obtained	NULL
by	NULL
leukophoresis	NULL
of	NULL
healthy	NULL
donors	NULL
aged	NULL
21	NULL
to	NULL
31	NULL
years	NULL
.	NULL

Purified	NULL
T	NULL
cells	NULL
were	NULL
then	NULL
isolated	NULL
from	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
by	NULL
negative	NULL
selection	NULL
with	NULL
immunoabsorption	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Cell	NULL
VoL	NULL
.	NULL

66	NULL
,	NULL
1992	NULL
purification	NULL
was	NULL
routinely	NULL
monitored	NULL
by	NULL
flow	NULL
cytometry	NULL
and	NULL
histochemistry	NULL
.	NULL

Monocytes	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
large	NULL
granular	NULL
lym-phocytes	NULL
were	NULL
not	NULL
detectable	NULL
by	NULL
immunofluorescence	NULL
analysis	NULL
.	NULL

Viability	NULL
was	NULL
greater	NULL
than	NULL
99	NULL
%	NULL
as	NULL
measured	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
cultured	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
2	NULL
x	NULL
10°/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
GIBCO	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
G	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
pg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
15	NULL
mM	NULL
HEPES	NULL
(	NULL
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic	NULL
acid	NULL
;	NULL
pH	NULL
7.4	NULL
;	NULL
GIBCO	NULL
)	NULL
.	NULL

Freshly	NULL
isolated	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
by	NULL
culture	NULL
on	NULL
plates	NULL
coated	NULL
with	NULL
a	NULL
saturating	NULL
quantity	NULL
of	NULL
the	NULL
anti-CD3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MAb	NULL
)	NULL
G19-4	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
anti-CD28	NULL
MAb	NULL
9.3	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
for	NULL
6	NULL
to	NULL
8	NULL
h	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
24	NULL
)	NULL
or	NULL
by	NULL
treatment	NULL
for	NULL
6	NULL
to	NULL
8	NULL
h	NULL
with	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
;	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
0.4	NULL
pg/ml	NULL
)	NULL
,	NULL
or	NULL
both	NULL
.	NULL

Human	NULL
Jurkat	NULL
T-cell	NULL
tumor	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
penicillin-streptomycin	NULL
(	NULL
GIBCO	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
Elf-1	NULL
cDNA	NULL
clones	NULL
.	NULL

Elf-1	NULL
cDNA	NULL
clones	NULL
were	NULL
isolated	NULL
by	NULL
screening	NULL
a	NULL
Agtll	NULL
cDNA	NULL
library	NULL
from	NULL
PMA-ionomycin-activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
22	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Plasmids	NULL
.	NULL

The	NULL
pRSVBgal	NULL
reference	NULL
plasmid	NULL
in	NULL
which	NULL
the	NULL
bacterial	NULL
B-galactosidase	NULL
gene	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
LTR	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
21	NULL
)	NULL
.	NULL

A	NULL
truncated	NULL
version	NULL
of	NULL
the	NULL
human	NULL
Ets-1	NULL
cDNA	NULL
(	NULL
bp	NULL
864	NULL
to	NULL
1347	NULL
)	NULL
containing	NULL
a	NULL
consensus	NULL
eukaryotic	NULL
initiation	NULL
codon	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
was	NULL
prepared	NULL
by	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
using	NULL
the	NULL
following	NULL
synthetic	NULL
oligonucleotide	NULL
primers	NULL
:	NULL
5	NULL
'	NULL
primer	NULL
,	NULL
CCAAGCTITTGGATCCCACCATGGAGGACTATC	NULL
CGGCTGCCCTGCCC	NULL
;	NULL
3	NULL
'	NULL
primer	NULL
,	NULL
CCAAGCTTTCCCCA	NULL
GCCCCTTCAGTGC	NULL
.	NULL

This	NULL
truncated	NULL
cDNA	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
HindIII	NULL
site	NULL
of	NULL
pCDM7	NULL
for	NULL
use	NULL
in	NULL
in	NULL
vitro	NULL
transcription	NULL
and	NULL
translation	NULL
reactions	NULL
.	NULL

The	NULL
full-length	NULL
Elf-1	NULL
DNA	NULL
was	NULL
cloned	NULL
into	NULL
pcDNA1/neo	NULL
(	NULL
InVitrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
for	NULL
use	NULL
in	NULL
in	NULL
vitro	NULL
transcription	NULL
and	NULL
translation	NULL
reactions	NULL
.	NULL

The	NULL
wild-type	NULL
HIV-2CAT	NULL
plasmid	NULL
containing	NULL
bp	NULL
-556	NULL
to	NULL
+156	NULL
of	NULL
the	NULL
viral	NULL
LTR	NULL
from	NULL
the	NULL
ROD	NULL
strain	NULL
of	NULL
HIV-2	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Mutations	NULL
were	NULL
introduced	NULL
into	NULL
PuB1	NULL
and	NULL
PuB2	NULL
(	NULL
APuB	NULL
)	NULL
or	NULL
kB	NULL
(	NULL
A	NULL
«	NULL
B	NULL
)	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
by	NULL
using	NULL
oligonucleotide-mediated	NULL
gapped-heteroduplex	NULL
site-directed	NULL
mutagenesis	NULL
(	NULL
20	NULL
)	NULL
.	NULL

All	NULL
mutations	NULL
were	NULL
confirmed	NULL
by	NULL
DNA	NULL
sequence	NULL
analysis	NULL
.	NULL

Plasmid	NULL
DNA	NULL
for	NULL
use	NULL
in	NULL
transfections	NULL
was	NULL
prepared	NULL
by	NULL
cesium	NULL
chloride	NULL
density	NULL
gradient	NULL
centrifugation	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
.	NULL

Nuclei	NULL
were	NULL
isolated	NULL
from	NULL
cultured	NULL
T	NULL
cells	NULL
by	NULL
centrifugation	NULL
at	NULL
14,000	NULL
x	NULL
g	NULL
for	NULL
2	NULL
min	NULL
following	NULL
cell	NULL
lysis	NULL
with	NULL
40	NULL
mM	NULL
KCl	NULL
,	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.0	NULL
)	NULL
,	NULL
3	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
,	NULL
8	NULL
ug	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
,	NULL
2	NULL
mg	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
,	NULL
0.5	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
,	NULL
and	NULL
0.2	NULL
%	NULL
Nonidet	NULL
P-40	NULL
(	NULL
vol/vol	NULL
)	NULL
.	NULL

Nuclei	NULL
were	NULL
resuspended	NULL
in	NULL
a	NULL
solution	NULL
of	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
0.42	NULL
M	NULL
KCI	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
and	NULL
25	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
glycerol	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Extracts	NULL
were	NULL
cleared	NULL
by	NULL
centrifugation	NULL
at	NULL
14,000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
resulting	NULL
supernatants	NULL
were	NULL
dialyzed	NULL
for	NULL
4	NULL
h	NULL
at	NULL
4°C	NULL
against	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
0.1	NULL
M	NULL
KCl	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
and	NULL
20	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
glycerol	NULL
(	NULL
buffer	NULL
D	NULL
)	NULL
and	NULL
frozen	NULL
in	NULL
aliquots	NULL
at	NULL
-70°C	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
with	NULL
a	NULL
commercially	NULL
available	NULL
kit	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

EMSAs	NULL
.	NULL

The	NULL
following	NULL
double-stranded	NULL
oligonucleotides	NULL
containing	NULL
overhanging	NULL
BamHI-Bgi/lII	NULL
ends	NULL
were	NULL
synthesized	NULL
Elf-1	NULL
BINDS	NULL
REGULATORY	NULL
MOTIFS	NULL
IN	NULL
HIV-2	NULL
LTR	NULL
5891	NULL
104	NULL
90	NULL
250	NULL
1	NULL
hHIva	NULL
LTR	NULL
-	NULL
|	NULL
1	NULL
1	NULL
_	NULL
{	NULL
[	NULL
1	NULL
|	NULL
El-1	NULL
KL	NULL
T1	NULL
TATA	NULL
_L	NULL
,	NULL
/	NULL
1	NULL
uveure	NULL
[	NULL
___	NULL
R	NULL
RJ	NULL
MMH	NULL
I	NULL
|	NULL
~170-145-110	NULL
+30	NULL
-	NULL
»	NULL
PuBi	NULL
PuB2	NULL
T-	NULL
raract	NULL
res	NULL
scresas	NULL
carte	NULL
.	NULL

AtcT	NULL
IL-2	NULL
Enh	NULL
:	NULL
(	NULL
NFAT-1	NULL
)	NULL
{	NULL
IL-2B	NULL
)	NULL
GM-CSF	NULL
Pr	NULL
:	NULL
IL-3	NULL
Pr	NULL
:	NULL
HIV-2	NULL
LTR	NULL
:	NULL
(	NULL
CD3R	NULL
)	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Identification	NULL
of	NULL
purine	NULL
boxes	NULL
in	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
illustration	NULL
of	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
enhancers	NULL
.	NULL

The	NULL
locations	NULL
of	NULL
the	NULL
TATAA	NULL
box	NULL
(	NULL
TATA	NULL
)	NULL
,	NULL
Spl	NULL
,	NULL
and	NULL
kB	NULL
binding	NULL
sites	NULL
are	NULL
from	NULL
Markovitz	NULL
et	NULL
al	NULL
.	NULL

(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
(	NULL
bp	NULL
-100	NULL
to	NULL
-176	NULL
)	NULL
is	NULL
from	NULL
Guyader	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
purine	NULL
boxes	NULL
(	NULL
PuBl	NULL
and	NULL
PuB2	NULL
)	NULL
and	NULL
the	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
are	NULL
boxed	NULL
.	NULL

Nucleotide	NULL
substitutions	NULL
used	NULL
to	NULL
produce	NULL
mutant	NULL
enhancers	NULL
are	NULL
shown	NULL
below	NULL
the	NULL
wild-type	NULL
sequence	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Comparison	NULL
of	NULL
the	NULL
purine	NULL
boxes	NULL
in	NULL
four	NULL
inducible	NULL
T-cell	NULL
enhancers	NULL
.	NULL

Purine	NULL
boxes	NULL
from	NULL
the	NULL
human	NULL
IL-2	NULL
(	NULL
12	NULL
)	NULL
,	NULL
human	NULL
GM-CSF	NULL
(	NULL
34	NULL
)	NULL
,	NULL
and	NULL
human	NULL
IL-3	NULL
(	NULL
35	NULL
)	NULL
promoter	NULL
(	NULL
Pr	NULL
)	NULL
-enhancers	NULL
(	NULL
Enh	NULL
)	NULL
are	NULL
compared	NULL
with	NULL
those	NULL
from	NULL
the	NULL
HIV-2	NULL
LTR	NULL
.	NULL

The	NULL
shared	NULL
purine-rich	NULL
core	NULL
pentanucleotide	NULL
is	NULL
shaded	NULL
.	NULL

Previous	NULL
names	NULL
for	NULL
these	NULL
elements	NULL
are	NULL
shown	NULL
in	NULL
parentheses	NULL
at	NULL
the	NULL
right	NULL
.	NULL

on	NULL
an	NULL
Applied	NULL
Biosystems	NULL
model	NULL
380B	NULL
DNA	NULL
synthesizer	NULL
and	NULL
labeled	NULL
with	NULL
*°P-nucleotides	NULL
by	NULL
fill	NULL
in	NULL
with	NULL
the	NULL
Klenow	NULL
fragment	NULL
of	NULL
DNA	NULL
polymerase	NULL
I	NULL
prior	NULL
to	NULL
use	NULL
in	NULL
EMSAs	NULL
:	NULL
Ta2	NULL
,	NULL
CCTCTTCTTTCCAGAGGATGTGGCTTCTGCGA	NULL
;	NULL
PuB1	NULL
,	NULL
CCATITTAGTTAAAGACAGGAACAGCTAT	NULL
;	NULL
PUB2	NULL
,	NULL
CA	NULL
GCTATACTTGGTCAGGGCAGGAAGTAACTA	NULL
.	NULL

Binding	NULL
reactions	NULL
using	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
contained	NULL
1	NULL
to	NULL
1.5	NULL
ug	NULL
of	NULL
T-cell	NULL
nuclear	NULL
protein	NULL
,	NULL
20,000	NULL
dpm	NULL
(	NULL
0.1	NULL
to	NULL
0.5	NULL
ng	NULL
)	NULL
of	NULL
radiolabeled	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
and	NULL
250	NULL
ng	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
50	NULL
mM	NULL
KCl-10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
-10	NULL
mM	NULL
HEPES-1.25	NULL
mM	NULL
DTT-1.1	NULL
mM	NULL
EDTA-15	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
glycerol	NULL
in	NULL
a	NULL
final	NULL
reaction	NULL
volume	NULL
of	NULL
20	NULL
pl	NULL
.	NULL

Following	NULL
incubation	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
,	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
fractionated	NULL
by	NULL
electrophoresis	NULL
in	NULL
nondenaturing	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
at	NULL
100	NULL
V	NULL
for	NULL
2.5	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
TGE	NULL
buffer	NULL
(	NULL
0.05	NULL
M	NULL
Tris	NULL
,	NULL
0.5	NULL
M	NULL
glycine	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
)	NULL
with	NULL
47	NULL
wM	NULL
B-mercaptoethanol	NULL
.	NULL

Binding	NULL
reactions	NULL
using	NULL
in	NULL
vitro-transcribed	NULL
and	NULL
-translated	NULL
Elf-1	NULL
and	NULL
Ets-1	NULL
proteins	NULL
contained	NULL
3	NULL
pl	NULL
of	NULL
in	NULL
vitro-translated	NULL
protein	NULL
,	NULL
20,000	NULL
dpm	NULL
of	NULL
radiolabeled	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
and	NULL
250	NULL
ng	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
75	NULL
mM	NULL
KCl-10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
-1	NULL
mM	NULL
DTT-1	NULL
mM	NULL
EDTA-4	NULL
%	NULL
Ficoll	NULL
.	NULL

Following	NULL
incubation	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
DNA	NULL
protein	NULL
complexes	NULL
were	NULL
fractionated	NULL
by	NULL
electrophoresis	NULL
in	NULL
4	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gels	NULL
which	NULL
were	NULL
run	NULL
in	NULL
0.25	NULL
%	NULL
TBE	NULL
buffer	NULL
(	NULL
25	NULL
mM	NULL
Tris	NULL
,	NULL
25	NULL
mM	NULL
boric	NULL
acid	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
)	NULL
at	NULL
110	NULL
V	NULL
for	NULL
4	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

All	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
subjected	NULL
to	NULL
autoradiography	NULL
with	NULL
intensifying	NULL
screens	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
21	NULL
)	NULL
.	NULL

5892	NULL
LEIDEN	NULL
ET	NULL
AL	NULL
.	NULL

Transfections	NULL
and	NULL
CAT	NULL
assays	NULL
.	NULL

Exponentially	NULL
growing	NULL
cultures	NULL
containing	NULL
10	NULL
``	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
reporter	NULL
plasmid	NULL
and	NULL
1	NULL
pg	NULL
of	NULL
the	NULL
pRSVBgal	NULL
reference	NULL
plasmid	NULL
by	NULL
using	NULL
DEAE-dextran	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Thirty	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
medium	NULL
alone	NULL
or	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
,	NULL
or	NULL
they	NULL
were	NULL
cultured	NULL
in	NULL
plastic	NULL
tissue	NULL
culture	NULL
dishes	NULL
coated	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
the	NULL
G19-4	NULL
anti-CD3	NULL
MAb	NULL
per	NULL
ml	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
12	NULL
h	NULL
after	NULL
stimulation	NULL
,	NULL
and	NULL
cell	NULL
extracts	NULL
normalized	NULL
for	NULL
protein	NULL
content	NULL
with	NULL
a	NULL
commercially	NULL
available	NULL
kit	NULL
(	NULL
Bio-Rad	NULL
)	NULL
were	NULL
assayed	NULL
for	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
and	NULL
B-galactosidase	NULL
activities	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
21	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
and	NULL
translation	NULL
reactions	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
a	NULL
commercially	NULL
available	NULL
kit	NULL
(	NULL
InVitrogen	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

In	NULL
vitro	NULL
translation	NULL
reactions	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
commercially	NULL
available	NULL
rabbit	NULL
reticulocyte	NULL
system	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Production	NULL
of	NULL
recombinant	NULL
Eif-1	NULL
protein	NULL
and	NULL
Elf-1-specific	NULL
rabbit	NULL
antiserum	NULL
.	NULL

For	NULL
production	NULL
of	NULL
recombinant	NULL
Elf-1	NULL
protein	NULL
for	NULL
immunization	NULL
,	NULL
the	NULL
Elf-1	NULL
cDNA	NULL
was	NULL
excised	NULL
from	NULL
pcDNAl/neo	NULL
by	NULL
digestion	NULL
with	NULL
EcoRV	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
the	NULL
pET-3b	NULL
vector	NULL
(	NULL
38	NULL
)	NULL
(	NULL
following	NULL
blunting	NULL
with	NULL
the	NULL
Klenow	NULL
fragment	NULL
of	NULL
DNA	NULL
polymerase	NULL
I	NULL
)	NULL
.	NULL

The	NULL
resulting	NULL
plasmid	NULL
was	NULL
transformed	NULL
into	NULL
competent	NULL
BL21	NULL
(	NULL
DE3	NULL
)	NULL
bacteria	NULL
,	NULL
and	NULL
a	NULL
single	NULL
colony	NULL
was	NULL
grown	NULL
in	NULL
M9ZB	NULL
medium	NULL
containing	NULL
100	NULL
ug	NULL
of	NULL
carbenicillin	NULL
per	NULL
ml	NULL
to	NULL
an	NULL
optical	NULL
density	NULL
at	NULL
600	NULL
nm	NULL
of	NULL
0.5	NULL
.	NULL

Isopropyl-B-p-thiogalac-topyranoside	NULL
(	NULL
IPTG	NULL
)	NULL
was	NULL
added	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
2	NULL
mM	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
grown	NULL
at	NULL
37°C	NULL
for	NULL
2.5	NULL
h	NULL
with	NULL
shaking	NULL
.	NULL

Cells	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
at	NULL
4,000	NULL
rpm	NULL
in	NULL
a	NULL
microcentrifuge	NULL
(	NULL
Eppendorf	NULL
)	NULL
and	NULL
lysed	NULL
in	NULL
50	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
-1	NULL
mM	NULL
EDTA-1	NULL
mM	NULL
DTT-1	NULL
mM	NULL
PMSF-260	NULL
mg	NULL
of	NULL
lysozyme	NULL
per	NULL
ml	NULL
.	NULL

Inclusion	NULL
bodies	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
at	NULL
4,000	NULL
rpm	NULL
in	NULL
a	NULL
microcentrifuge	NULL
.	NULL

Proteins	NULL
were	NULL
denatured	NULL
and	NULL
solubilized	NULL
in	NULL
6	NULL
M	NULL
urea	NULL
and	NULL
then	NULL
renatured	NULL
by	NULL
dialysis	NULL
against	NULL
buffer	NULL
D	NULL
overnight	NULL
at	NULL
4°C	NULL
prior	NULL
to	NULL
being	NULL
frozen	NULL
in	NULL
aliquots	NULL
at	NULL
-70°C	NULL
.	NULL

Control	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
BL21	NULL
(	NULL
DE3	NULL
)	NULL
bacteria	NULL
containing	NULL
the	NULL
pET-3b	NULL
plasmid	NULL
without	NULL
a	NULL
cDNA	NULL
insert	NULL
.	NULL

Rabbits	NULL
were	NULL
immunized	NULL
with	NULL
three	NULL
sequential	NULL
subcutaneous	NULL
injections	NULL
of	NULL
100	NULL
to	NULL
150	NULL
pug	NULL
of	NULL
renatured	NULL
recombinant	NULL
Elf-1	NULL
protein	NULL
in	NULL
complete	NULL
(	NULL
first	NULL
immu-nization	NULL
)	NULL
or	NULL
incomplete	NULL
(	NULL
second	NULL
and	NULL
third	NULL
immunizations	NULL
)	NULL
Freund	NULL
's	NULL
adjuvant	NULL
.	NULL

Serum	NULL
was	NULL
collected	NULL
9	NULL
days	NULL
after	NULL
the	NULL
third	NULL
immunization	NULL
.	NULL

This	NULL
serum	NULL
was	NULL
shown	NULL
to	NULL
specifically	NULL
immunoprecipitate	NULL
in	NULL
vitro-translated	NULL
Elf-1	NULL
but	NULL
not	NULL
Ets-1	NULL
or	NULL
Ets-2	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
control	NULL
experiments	NULL
,	NULL
this	NULL
serum	NULL
did	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
binding	NULL
of	NULL
Ets-1	NULL
or	NULL
members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
in	NULL
EMSAs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
accession	NULL
number	NULL
.	NULL

The	NULL
complete	NULL
nucleotide	NULL
sequence	NULL
of	NULL
Elf-1	NULL
is	NULL
available	NULL
through	NULL
GenBank	NULL
,	NULL
accession	NULL
number	NULL
MS82882	NULL
.	NULL

RESULTS	NULL
Two	NULL
purine-rich	NULL
sequence	NULL
motifs	NULL
are	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
.	NULL

A	NULL
comparison	NULL
of	NULL
the	NULL
sequences	NULL
of	NULL
the	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
enhancers	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
demonstrated	NULL
the	NULL
absence	NULL
of	NULL
one	NULL
of	NULL
the	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
HIV-2	NULL
compared	NULL
with	NULL
HIV-1	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
contains	NULL
two	NULL
purine-rich	NULL
sequence	NULL
motifs	NULL
,	NULL
PuB1l	NULL
and	NULL
PuB2	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
recently	NULL
described	NULL
consensus	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
18	NULL
,	NULL
20	NULL
,	NULL
26	NULL
,	NULL
27	NULL
,	NULL
41	NULL
,	NULL
44	NULL
)	NULL
.	NULL

These	NULL
two	NULL
motifs	NULL
are	NULL
conserved	NULL
in	NULL
at	NULL
least	NULL
J.	NULL
Viror	NULL
.	NULL

eight	NULL
strains	NULL
of	NULL
HIV-2	NULL
but	NULL
are	NULL
absent	NULL
from	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
.	NULL

Similar	NULL
motifs	NULL
are	NULL
also	NULL
present	NULL
in	NULL
the	NULL
transcriptional	NULL
enhancers	NULL
of	NULL
several	NULL
other	NULL
inducible	NULL
T-cell	NULL
genes	NULL
including	NULL
those	NULL
of	NULL
the	NULL
human	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
granulocyte	NULL
macrophage-colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
genes	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

To	NULL
test	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
purine	NULL
boxes	NULL
and	NULL
the	NULL
NF-kB	NULL
site	NULL
for	NULL
inducibility	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
,	NULL
we	NULL
prepared	NULL
CAT	NULL
reporter	NULL
constructs	NULL
containing	NULL
either	NULL
the	NULL
wild-type	NULL
HIV-2	NULL
LTR	NULL
or	NULL
mutant	NULL
LTRs	NULL
with	NULL
nucleotide	NULL
substitutions	NULL
in	NULL
the	NULL
PuB1	NULL
and	NULL
PuB2	NULL
(	NULL
APuB	NULL
)	NULL
or	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
A	NULL
«	NULL
B	NULL
)	NULL
binding	NULL
sites	NULL
.	NULL

These	NULL
reporter	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
human	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Portions	NULL
of	NULL
the	NULL
transfected	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
medium	NULL
alone	NULL
,	NULL
while	NULL
other	NULL
portions	NULL
were	NULL
activated	NULL
by	NULL
treatment	NULL
with	NULL
PMA	NULL
or	NULL
by	NULL
cross-linking	NULL
of	NULL
the	NULL
TCR	NULL
complex	NULL
by	NULL
treatment	NULL
with	NULL
the	NULL
anti-CD3	NULL
antibody	NULL
G19-4	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
previous	NULL
results	NULL
(	NULL
30	NULL
)	NULL
,	NULL
the	NULL
wild-type	NULL
HIV-2	NULL
enhancer	NULL
was	NULL
induced	NULL
50-	NULL
to	NULL
100-fold	NULL
following	NULL
T-cell	NULL
activation	NULL
with	NULL
either	NULL
PMA	NULL
or	NULL
the	NULL
anti-CD3	NULL
MAb	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
NF-KB	NULL
site	NULL
reduced	NULL
PMA	NULL
inducibility	NULL
by	NULL
more	NULL
than	NULL
90	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
had	NULL
a	NULL
similar	NULL
effect	NULL
on	NULL
inducibility	NULL
following	NULL
TCR	NULL
cross-linking	NULL
(	NULL
30	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
both	NULL
purine	NULL
boxes	NULL
abolished	NULL
the	NULL
inducibility	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
mutation	NULL
of	NULL
either	NULL
purine	NULL
box	NULL
alone	NULL
decreased	NULL
but	NULL
did	NULL
not	NULL
abolish	NULL
inducible	NULL
enhancer	NULL
activity	NULL
following	NULL
either	NULL
PMA	NULL
treatment	NULL
or	NULL
TCR	NULL
cross-linking	NULL
(	NULL
30a	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
both	NULL
the	NULL
NF-KB	NULL
binding	NULL
site	NULL
and	NULL
at	NULL
least	NULL
one	NULL
purine	NULL
box	NULL
are	NULL
required	NULL
for	NULL
the	NULL
inducibility	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
following	NULL
signaling	NULL
through	NULL
the	NULL
TCR	NULL
complex	NULL
or	NULL
activation	NULL
with	NULL
phorbol	NULL
esters	NULL
.	NULL

A	NULL
novel	NULL
Ets	NULL
family	NULL
member	NULL
,	NULL
Elf-1	NULL
,	NULL
binds	NULL
to	NULL
the	NULL
purine	NULL
boxes	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
.	NULL

Two	NULL
Ets	NULL
family	NULL
members	NULL
,	NULL
Ets-1	NULL
and	NULL
Ets-2	NULL
,	NULL
were	NULL
known	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Several	NULL
types	NULL
of	NULL
experiments	NULL
were	NULL
performed	NULL
to	NULL
determine	NULL
whether	NULL
either	NULL
of	NULL
these	NULL
proteins	NULL
bound	NULL
to	NULL
the	NULL
purine	NULL
boxes	NULL
in	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

First	NULL
,	NULL
recombinant	NULL
and	NULL
in	NULL
vitro-transcribed	NULL
and	NULL
-translated	NULL
Ets-1	NULL
and	NULL
Ets-2	NULL
proteins	NULL
were	NULL
used	NULL
in	NULL
EMSAs	NULL
with	NULL
radiolabeled	NULL
probes	NULL
containing	NULL
PuBl	NULL
and	NULL
PuB2	NULL
.	NULL

Neither	NULL
Ets-1	NULL
nor	NULL
Ets-2	NULL
bound	NULL
efficiently	NULL
to	NULL
the	NULL
purine	NULL
boxes	NULL
from	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
these	NULL
same	NULL
protein	NULL
preparations	NULL
bound	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
the	NULL
Ta2	NULL
(	NULL
20	NULL
)	NULL
site	NULL
from	NULL
the	NULL
TCR	NULL
a	NULL
enhancer	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
a	NULL
second	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
anti-Ets-1	NULL
and	NULL
anti-Ets-2	NULL
MAbs	NULL
were	NULL
used	NULL
in	NULL
EMSA	NULL
experiments	NULL
utilizing	NULL
radiolabeled	NULL
PuBl	NULL
and	NULL
PuB2	NULL
probes	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
PMA-activated	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

Neither	NULL
of	NULL
these	NULL
antibodies	NULL
caused	NULL
alterations	NULL
in	NULL
the	NULL
binding	NULL
and/or	NULL
mobility	NULL
of	NULL
the	NULL
major	NULL
T-cell	NULL
nuclear	NULL
protein	NULL
complex	NULL
that	NULL
bound	NULL
to	NULL
PuB1l	NULL
and	NULL
PuB2	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
experiments	NULL
demonstrated	NULL
that	NULL
neither	NULL
Ets-1	NULL
nor	NULL
Ets-2	NULL
is	NULL
involved	NULL
in	NULL
regulating	NULL
the	NULL
inducibility	NULL
of	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
and	NULL
suggested	NULL
the	NULL
possibility	NULL
that	NULL
there	NULL
are	NULL
novel	NULL
Ets-related	NULL
nuclear	NULL
proteins	NULL
that	NULL
interact	NULL
with	NULL
PuB1	NULL
and	NULL
PuB2	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
we	NULL
screened	NULL
an	NULL
activated	NULL
Jurkat	NULL
T-cell	NULL
cDNA	NULL
library	NULL
by	NULL
low-stringency	NULL
hybridization	NULL
with	NULL
a	NULL
probe	NULL
from	NULL
the	NULL
DNA-binding	NULL
domain	NULL
of	NULL
Ets-1	NULL
.	NULL

One	NULL
cDNA	NULL
clone	NULL
isolated	NULL
by	NULL
this	NULL
approach	NULL
was	NULL
shown	NULL
to	NULL
contain	NULL
an	NULL
Ets	NULL
basic	NULL
domain	NULL
with	NULL
39	NULL
of	NULL
42	NULL
amino	NULL
acids	NULL
identical	NULL
to	NULL
those	NULL
of	NULL
the	NULL
ecdysone-inducible	NULL
transcription	NULL
factor	NULL
E74	NULL
,	NULL
which	NULL
is	NULL
required	NULL
for	NULL
Drosophila	NULL
metamorphosis	NULL
(	NULL
7	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
named	NULL
this	NULL
clone	NULL
E74-like	NULL
factor-1	NULL
(	NULL
Elf-1	NULL
)	NULL
(	NULL
40	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
the	NULL
full-length	NULL
3.6-kb	NULL
Elf-1	NULL
cDNA	NULL
contains	NULL
a	NULL
315-bp	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
,	NULL
a	NULL
single	NULL
long	NULL
open	NULL
reading	NULL
frame	NULL
of	NULL
1,857	NULL
bp	NULL
,	NULL
and	NULL
a	NULL
1,392-bp	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
.	NULL

The	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
Elf-1	NULL
includes	NULL
a	NULL
basic	NULL
domain	NULL
that	NULL
is	NULL
related	NULL
to	NULL
those	NULL
of	NULL
the	NULL
other	NULL
Ets	NULL
family	NULL
members	NULL
as	NULL
well	NULL
as	NULL
an	NULL
a-helical	NULL
domain	NULL
Vor	NULL
.	NULL

66	NULL
,	NULL
1992	NULL
Elf-1	NULL
BINDS	NULL
REGULATORY	NULL
MOTIFS	NULL
IN	NULL
HIV-2	NULL
LTR	NULL
5893	NULL
Relative	NULL
Cat	NULL
Activity	NULL
Stimulation	NULL
ro	NULL
p	NULL
r	NULL
co	NULL
0	NULL
aes	NULL
o	NULL
led	NULL
led	NULL
0	NULL
0	NULL
HIV-2CAT	NULL
:	NULL
‘	NULL
a-CD3	NULL
2	NULL
#	NULL
0	NULL
PMA	NULL
<	NULL
$	NULL
@	NULL
AxB	NULL
&	NULL
@	NULL
PMA	NULL
‘	NULL
APuB	NULL
:	NULL
e-CD3	NULL
‘	NULL
PMA	NULL
3	NULL
.	NULL

FIG	NULL
.	NULL

2	NULL
.	NULL

Functional	NULL
significance	NULL
of	NULL
the	NULL
xB	NULL
and	NULL
PuB	NULL
sites	NULL
in	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

Jurkat	NULL
human	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
reporter	NULL
plasmids	NULL
by	NULL
using	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
DEAE-dextran	NULL
protocol	NULL
.	NULL

Thirty	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
-	NULL
)	NULL
or	NULL
PMA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
were	NULL
cultured	NULL
in	NULL
plastic	NULL
tissue	NULL
culture	NULL
dishes	NULL
coated	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
the	NULL
G19-4	NULL
anti-CD3	NULL
MAb	NULL
per	NULL
ml	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
12	NULL
h	NULL
after	NULL
stimulation	NULL
,	NULL
and	NULL
cell	NULL
extracts	NULL
normalized	NULL
for	NULL
protein	NULL
content	NULL
by	NULL
using	NULL
a	NULL
commercially	NULL
available	NULL
kit	NULL
(	NULL
Bio-Rad	NULL
)	NULL
were	NULL
assayed	NULL
for	NULL
CAT	NULL
and	NULL
B-galactosidase	NULL
activities	NULL
.	NULL

The	NULL
data	NULL
are	NULL
shown	NULL
as	NULL
CAT	NULL
activity	NULL
relative	NULL
to	NULL
that	NULL
of	NULL
the	NULL
medium-treated	NULL
control	NULL
following	NULL
normalization	NULL
for	NULL
differences	NULL
in	NULL
transfection	NULL
efficiencies	NULL
.	NULL

Autoradiograms	NULL
of	NULL
representative	NULL
CAT	NULL
assays	NULL
are	NULL
shown	NULL
at	NULL
the	NULL
right	NULL
.	NULL

immediately	NULL
5	NULL
'	NULL
of	NULL
the	NULL
basic	NULL
region	NULL
that	NULL
is	NULL
also	NULL
conserved	NULL
in	NULL
most	NULL
of	NULL
the	NULL
other	NULL
Ets	NULL
proteins	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
two	NULL
regions	NULL
,	NULL
previously	NULL
termed	NULL
the	NULL
ETS	NULL
domain	NULL
,	NULL
represent	NULL
the	NULL
DNA-binding	NULL
domain	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
26	NULL
,	NULL
45	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
E74	NULL
binds	NULL
to	NULL
a	NULL
purine-rich	NULL
sequence	NULL
(	NULL
ACGAATCAGGAAAACTG	NULL
)	NULL
that	NULL
contains	NULL
a	NULL
core	NULL
pentanucleotide	NULL
that	NULL
is	NULL
identical	NULL
to	NULL
PuB1	NULL
and	NULL
PuB2	NULL
(	NULL
44	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
reasoned	NULL
that	NULL
Elf-1	NULL
might	NULL
bind	NULL
preferentially	NULL
to	NULL
the	NULL
purine	NULL
boxes	NULL
from	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
in	NULL
vitro-transcribed	NULL
and	NULL
-translated	NULL
Elf-1	NULL
protein	NULL
bound	NULL
to	NULL
PuB1	NULL
and	NULL
PuB2	NULL
but	NULL
not	NULL
to	NULL
the	NULL
Ta2	NULL
Ets-1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
human	NULL
TCR	NULL
a	NULL
enhancer	NULL
.	NULL

Conversely	NULL
,	NULL
Ets-1	NULL
bound	NULL
to	NULL
Ta2	NULL
but	NULL
failed	NULL
to	NULL
bind	NULL
to	NULL
PuBl	NULL
or	NULL
PuB2	NULL
.	NULL

Binding	NULL
of	NULL
Elf-1	NULL
to	NULL
PuB2	NULL
was	NULL
efficiently	NULL
inhibited	NULL
by	NULL
unlabeled	NULL
PuB2	NULL
and	NULL
PuB1	NULL
oligonucleotide	NULL
competitors	NULL
but	NULL
not	NULL
by	NULL
competitors	NULL
containing	NULL
nucleotide	NULL
substitutions	NULL
within	NULL
the	NULL
core	NULL
of	NULL
PuBl	NULL
or	NULL
PuB2	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1A	NULL
for	NULL
the	NULL
nucleotide	NULL
substitutions	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
an	NULL
antiserum	NULL
raised	NULL
against	NULL
recombinant	NULL
Elf-1	NULL
protein	NULL
specifically	NULL
inhibited	NULL
binding	NULL
of	NULL
in	NULL
vitro-transcribed	NULL
and	NULL
-translated	NULL
Elf-1	NULL
to	NULL
PuB2	NULL
and	NULL
also	NULL
inhibited	NULL
binding	NULL
of	NULL
the	NULL
major	NULL
nuclear	NULL
protein	NULL
complex	NULL
from	NULL
PMA-activated	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
to	NULL
this	NULL
same	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
PuB2	NULL
binding	NULL
complex	NULL
from	NULL
activated	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
produced	NULL
by	NULL
in	NULL
vitro-translated	NULL
Elf-1	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

In	NULL
control	NULL
experiments	NULL
,	NULL
preimmune	NULL
rabbit	NULL
serum	NULL
as	NULL
well	NULL
as	NULL
anti-Ets-1	NULL
,	NULL
anti-Ets-2	NULL
,	NULL
and	NULL
anti-IL-2-receptor	NULL
antibodies	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
Elf-1	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
experiments	NULL
demonstrated	NULL
that	NULL
Elf-1	NULL
present	NULL
in	NULL
activated	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
binds	NULL
preferentially	NULL
and	NULL
specifically	NULL
to	NULL
the	NULL
purine	NULL
boxes	NULL
from	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
Elf-1	NULL
binding	NULL
sites	NULL
are	NULL
required	NULL
for	NULL
trans	NULL
activation	NULL
of	NULL
the	NULL
enhancer	NULL
following	NULL
T-cell	NULL
activation	NULL
.	NULL

DISCUSSION	NULL
In	NULL
the	NULL
studies	NULL
described	NULL
in	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
two	NULL
purine-rich	NULL
sequence	NULL
motifs	NULL
corresponding	NULL
to	NULL
Ets-bind-ing	NULL
sites	NULL
that	NULL
are	NULL
required	NULL
for	NULL
the	NULL
inducible	NULL
expression	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
.	NULL

These	NULL
sites	NULL
bind	NULL
a	NULL
novel	NULL
Ets-related	NULL
family	NULL
member	NULL
,	NULL
Elf-1	NULL
,	NULL
but	NULL
fail	NULL
to	NULL
bind	NULL
the	NULL
closely	NULL
related	NULL
Ets-1	NULL
transcription	NULL
factor	NULL
.	NULL

Importantly	NULL
,	NULL
Elf-1	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
only	NULL
protein	NULL
in	NULL
activated	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
that	NULL
binds	NULL
to	NULL
these	NULL
sites	NULL
in	NULL
EMSAs	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
30	NULL
)	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
Elf-1-binding	NULL
sites	NULL
,	NULL
HIV-2	NULL
activation	NULL
also	NULL
requires	NULL
an	NULL
intact	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
.	NULL

These	NULL
results	NULL
have	NULL
several	NULL
implications	NULL
for	NULL
the	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
HIV-2	NULL
activation	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
for	NULL
understanding	NULL
the	NULL
role	NULL
of	NULL
Ets	NULL
family	NULL
members	NULL
in	NULL
regulating	NULL
inducible	NULL
gene	NULL
expression	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
preponderance	NULL
of	NULL
evidence	NULL
from	NULL
several	NULL
experimental	NULL
systems	NULL
suggests	NULL
that	NULL
Ets	NULL
family	NULL
members	NULL
activate	NULL
transcription	NULL
by	NULL
working	NULL
in	NULL
concert	NULL
with	NULL
other	NULL
non-Ets	NULL
DNA-binding	NULL
proteins	NULL
.	NULL

Thus	NULL
,	NULL
for	NULL
example	NULL
,	NULL
Ets-1	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
cooperate	NULL
with	NULL
AP-1	NULL
to	NULL
activate	NULL
transcription	NULL
of	NULL
the	NULL
poly-omavirus	NULL
enhancer	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
GABPa	NULL
,	NULL
a	NULL
novel	NULL
Ets	NULL
family	NULL
member	NULL
,	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
to	NULL
cooperate	NULL
with	NULL
GABPB	NULL
and	NULL
VP16	NULL
to	NULL
activate	NULL
HSV-1	NULL
immediate-early	NULL
genes	NULL
(	NULL
41	NULL
)	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
suggest	NULL
that	NULL
Elf-1	NULL
can	NULL
also	NULL
function	NULL
cooperatively	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
to	NULL
activate	NULL
transcription	NULL
of	NULL
the	NULL
HIV-2	NULL
LTR	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
requirement	NULL
for	NULL
both	NULL
proteins	NULL
may	NULL
explain	NULL
in	NULL
part	NULL
why	NULL
overexpression	NULL
of	NULL
Elf-1	NULL
alone	NULL
fails	NULL
to	NULL
activate	NULL
the	NULL
HIV-2	NULL
LTR	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
is	NULL
worth	NULL
noting	NULL
that	NULL
recent	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
Elf-1	NULL
interacts	NULL
with	NULL
the	NULL
product	NULL
of	NULL
the	NULL
retinoblas-toma	NULL
gene	NULL
(	NULL
45a	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
regulation	NULL
of	NULL
Elf-1-dependent	NULL
transcriptional	NULL
activation	NULL
is	NULL
complex	NULL
and	NULL
can	NULL
not	NULL
be	NULL
dupli-	NULL
5894	NULL
LEIDEN	NULL
ET	NULL
AL	NULL
.	NULL

GECGGCCGCTCTACAGGAGCCATTTTAACAGCTAAAACTTGTCGGATTGCTTTTTATTTTCAAGCTCAAAAGACGATAGAGAAAGAATACTTGAAGGCCA	NULL
AGAAGCTTGAGAGAAGAAAAATTTCAGAAAAATTGTCTCAATTTGACTAGAATATCAATGAACCAGGAAAACTGAAGCACCTTCCCTAAAGAAAACTTGG	NULL
GTATACAATTACTCCACAGACAGAGCTGAGGGTTTTTTACCCAAATCAGTCACTGGATTTTGCTGCCTGATACGTGAATCTTCTTGGAATTTTTCTCATG	NULL
TGGATCTAAGGGGAATGCTTTATT	NULL
ATG	NULL
GCT	NULL
GCT	NULL
GTT	NULL
GTC	NULL
CAA	NULL
CAG	NULL
AAC	NULL
GAC	NULL
CTA	NULL
GTA	NULL
TTT	NULL
GAA	NULL
TTT	NULL
GCT	NULL
AGT	NULL
AAC	NULL
GTC	NULL
ATG	NULL
Mo	NULL
A	NULL
A	NULL
vo	NULL
vo	NULL
o	NULL
=o	NULL
N	NULL
D	NULL
Lo-	NULL
v	NULL
F	NULL
F	NULL
A	NULL
S	NULL
U	NULL
v	NULL
M	NULL
GAG	NULL
GAT	NULL
GAA	NULL
CGA	NULL
CAG	NULL
CTT	NULL
GGT	NULL
GAT	NULL
CCA	NULL
GCT	NULL
ATT	NULL
TTT	NULL
CCT	NULL
GCC	NULL
GTA	NULL
ATT	NULL
GTG	NULL
GAA	NULL
CAT	NULL
GTT	NULL
CCT	NULL
GGT	NULL
GCT	NULL
GAT	NULL
ATT	NULL
E	NULL
D	NULL
E	NULL
Ro	NULL
Q	NULL
L	NULL
G	NULL
D	NULL
P	NULL
A	NULL
I	NULL
F	NULL
P	NULL
A	NULL
V	NULL
I	NULL
v	NULL
OE	NULL
ho	NULL
V	NULL
OP	NULL
G	NULL
A	NULL
D	NULL
I	NULL
CTC	NULL
AAT	NULL
AGT	NULL
TAT	NULL
GCC	NULL
GGT	NULL
CTA	NULL
GCC	NULL
TGT	NULL
GTG	NULL
GAA	NULL
GAG	NULL
CCC	NULL
AAT	NULL
GAC	NULL
ATG	NULL
ATT	NULL
ACT	NULL
GAG	NULL
AGT	NULL
TCA	NULL
CTG	NULL
GAT	NULL
GTT	NULL
GCT	NULL
L	NULL
N	NULL
$	NULL
¥	NULL
A	NULL
G	NULL
Lo	NULL
A	NULL
_C	NULL
v	NULL
E	NULL
E	NULL
P	NULL
N	NULL
D	NULL
M	NULL
I	NULL
T	NULL
E	NULL
s	NULL
5	NULL
L	NULL
b	NULL
v	NULL
A	NULL
GAA	NULL
GAA	NULL
GAA	NULL
ATC	NULL
ATA	NULL
GAC	NULL
GAT	NULL
GAT	NULL
GAT	NULL
GAT	NULL
GAC	NULL
ATC	NULL
ACC	NULL
CTT	NULL
ACA	NULL
GTT	NULL
GAA	NULL
GCT	NULL
TCT	NULL
TGT	NULL
CAT	NULL
GAC	NULL
GGG	NULL
GAT	NULL
GAA	NULL
E	NULL
E	NULL
E	NULL
I	NULL
I	NULL
D	NULL
D	NULL
D	NULL
D	NULL
D	NULL
D	NULL
I	NULL
T	NULL
L	NULL
T	NULL
v	NULL
E	NULL
A	NULL
E	NULL
C	NULL
H	NULL
b	NULL
G	NULL
D	NULL
E	NULL
ACA	NULL
ATT	NULL
GAA	NULL
ACT	NULL
ATT	NULL
GAG	NULL
GCT	NULL
GCT	NULL
GAG	NULL
GCA	NULL
CTC	NULL
CTC	NULL
AAT	NULL
ATG	NULL
GAT	NULL
TCC	NULL
CCT	NULL
GGC	NULL
CCT	NULL
ATG	NULL
CTG	NULL
GAT	NULL
GAA	NULL
AAA	NULL
CGA	NULL
T	NULL
I	NULL
E	NULL
T	NULL
I	NULL
E	NULL
A	NULL
-	NULL
A	NULL
E	NULL
L	NULL
N	NULL
M	NULL
D	NULL
S	NULL
P	NULL
G	NULL
P	NULL
M	NULL
L	NULL
D	NULL
E	NULL
K	NULL
R	NULL
mre	NULL
GAC	NULL
ATG	NULL
GTT	NULL
GTT	NULL
GCC	NULL
CCA	NULL
GTC	NULL
ACC	NULL
CAT	NULL
GTG	NULL
TCC	NULL
GTC	NULL
ACA	NULL
TTA	NULL
ATA	NULL
AAT	NULL
AAT	NULL
AAT	NULL
ATA	NULL
TIT	NULL
AGT	NULL
TCA	NULL
CCT	NULL
P	NULL
D	NULL
Mo	NULL
v	NULL
v	NULL
aA	NULL
P	NULL
v	NULL
T	NULL
#	NULL
0	NULL
V	NULL
S	NULL
v	NULL
T	NULL
L	NULL
I	NULL
N	NULL
N	NULL
N	NULL
I	NULL
F	NULL
$	NULL
8	NULL
GAT	NULL
GGG	NULL
ATT	NULL
CCT	NULL
GAA	NULL
GTG	NULL
ATG	NULL
GAA	NULL
ACA	NULL
GTG	NULL
CAA	NULL
GAA	NULL
AAA	NULL
TAT	NULL
GCA	NULL
GAC	NULL
TCA	NULL
CCG	NULL
GGA	NULL
GCC	NULL
TCA	NULL
TCA	NULL
CCA	NULL
D	NULL
G	NULL
I	NULL
P	NULL
E	NULL
v	NULL
M	NULL
E	NULL
T	NULL
v	NULL
$	NULL
P	NULL
G	NULL
P	NULL
Q0	NULL
B	NULL
OK	NULL
Oy	NULL
aA	NULL
D	NULL
GAA	NULL
CAG	NULL
CCT	NULL
AAG	NULL
AGG	NULL
AAA	NULL
AAA	NULL
GGA	NULL
AGA	NULL
CCA	NULL
CCA	NULL
CGA	NULL
CCA	NULL
GAT	NULL
TCC	NULL
CCA	NULL
GCC	NULL
ACT	NULL
ACG	NULL
CCA	NULL
AAT	NULL
ATA	NULL
E	NULL
a	NULL
P	NULL
K	NULL
R	NULL
K	NULL
K	NULL
G	NULL
R	NULL
I	NULL
P	NULL
P	NULL
R	NULL
P	NULL
D	NULL
S	NULL
P	NULL
A	NULL
T	NULL
T	NULL
P	NULL
N	NULL
ACA	NULL
ATT	NULL
TAT	NULL
CTT	NULL
TGG	NULL
GAG	NULL
TIT	NULL
TTA	NULL
CTG	NULL
GCA	NULL
CTG	NULL
CTC	NULL
CAG	NULL
5	NULL
v	NULL
K	NULL
K	NULL
K	NULL
N	NULL
K	NULL
D	NULL
G	NULL
w	NULL
A	NULL
GAA	NULL
E	NULL
CAG	NULL
a	NULL
AAA	NULL
K	NULL
TCT	NULL
GTG	NULL
AAG	NULL
AAG	NULL
AAA	NULL
AAC	NULL
AAA	NULL
GAT	NULL
GGA	NULL
AAG	NULL
K	NULL
AAG	NULL
K	NULL
AAA	NULL
K	NULL
AAA	NULL
K	NULL
GAC	NULL
AAG	NULL
GCT	NULL
ACT	NULL
TGT	NULL
CCT	NULL
AAA	NULL
TAC	NULL
ATC	NULL
AG	NULL
CGA	NULL
GAG	NULL
AAA	NULL
GGC	NULL
ATT	NULL
TTT	NULL
AAA	NULL
TTG	NULL
GTG	NULL
GAT	NULL
TCT	NULL
AAA	NULL
D	NULL
K	NULL
A	NULL
T	NULL
C	NULL
P	NULL
K	NULL
Y	NULL
I	NULL
a	NULL
R	NULL
E	NULL
K	NULL
G	NULL
I	NULL
F	NULL
K	NULL
Lo	NULL
v	NULL
D	NULL
S	NULL
K	NULL
GCA	NULL
GTG	NULL
TCC	NULL
AGG	NULL
TTG	NULL
TGG	NULL
GGG	NULL
AAG	NULL
CAC	NULL
CCT	NULL
GAT	NULL
ATG	NULL
AAT	NULL
TAT	NULL
GAG	NULL
ACC	NULL
ATG	NULL
GGA	NULL
AGA	NULL
GCA	NULL
CTC	NULL
AGG	NULL
A	NULL
Vv	NULL
S	NULL
R	NULL
L	NULL
w	NULL
G	NULL
K	NULL
H	NULL
P	NULL
D	NULL
N	NULL
Y	NULL
E	NULL
T	NULL
M	NULL
G	NULL
R	NULL
A	NULL
L	NULL
R	NULL
TAC	NULL
TAT	NULL
TAC	NULL
CAA	NULL
AGG	NULL
GGT	NULL
ATT	NULL
CTG	NULL
GCA	NULL
GTG	NULL
GGT	NULL
CAG	NULL
GCG	NULL
TTG	NULL
GTG	NULL
TAT	NULL
CAG	NULL
TTT	NULL
AAA	NULL
GAA	NULL
ATG	NULL
CCA	NULL
AAA	NULL
Y	NULL
¥	NULL
Y	NULL
o	NULL
R	NULL
G	NULL
I	NULL
L	NULL
___A	NULL
v.	NULL
G	NULL
a	NULL
R	NULL
L	NULL
v.	NULL
Y	NULL
*	NULL
F	NULL
K	NULL
E	NULL
M	NULL
P	NULL
K	NULL
GAT	NULL
CTT	NULL
ATA	NULL
TAT	NULL
ATA	NULL
AAT	NULL
GAT	NULL
GAG	NULL
D	NULL
L	NULL
I	NULL
i	NULL
I	NULL
N	NULL
D	NULL
E	NULL
T	NULL
S	NULL
N	NULL
R	NULL
N	NULL
Q	NULL
T	NULL
E	NULL
R	NULL
S	NULL
R	NULL
S	NULL
$	NULL
§	NULL
P	NULL
G	NULL
v	NULL
K	NULL
G	NULL
G	NULL
A	NULL
T	NULL
T	NULL
v	NULL
CTA	NULL
AAA	NULL
CCA	NULL
GGG	NULL
AAT	NULL
TCT	NULL
AAA	NULL
GCT	NULL
GCA	NULL
AAA	NULL
CCC	NULL
AAA	NULL
GAT	NULL
CCT	NULL
GTG	NULL
GAM	NULL
GTT	NULL
GCA	NULL
CAA	NULL
CCA	NULL
TCA	NULL
GAA	NULL
GTT	NULL
TTG	NULL
AGG	NULL
L	NULL
K	NULL
P	NULL
G	NULL
N	NULL
$	NULL
Ko	NULL
A	NULL
A	NULL
K	NULL
P	NULL
K	NULL
D	NULL
P	NULL
v	NULL
P	NULL
El	NULL
E	NULL
v	NULL
L	NULL
R	NULL
ACA	NULL
GTG	NULL
CAG	NULL
CCC	NULL
ACG	NULL
CAG	NULL
TCT	NULL
CCA	NULL
TAT	NULL
CCT	NULL
ACC	NULL
CAG	NULL
CTC	NULL
TTC	NULL
CGG	NULL
ACT	NULL
GTT	NULL
CAT	NULL
GTA	NULL
GTA	NULL
CAG	NULL
CCA	NULL
GTA	NULL
CAG	NULL
GCT	NULL
T	NULL
v	NULL
o	NULL
P	NULL
T	NULL
a	NULL
S	NULL
P	NULL
¥	NULL
P	NULL
T	NULL
[	NULL
+l	NULL
L	NULL
OF	NULL
R	NULL
T	NULL
v	NULL
A	NULL
vo	NULL
v	NULL
o	NULL
P	NULL
v	NULL
a	NULL
A	NULL
GTC	NULL
CCA	NULL
GAG	NULL
GGA	NULL
GAA	NULL
GCA	NULL
GCT	NULL
AGA	NULL
ACC	NULL
AGT	NULL
ACC	NULL
ATG	NULL
v	NULL
P	NULL
A	NULL
A	NULL
T	NULL
M	NULL
CAG	NULL
GAT	NULL
GAA	NULL
ACA	NULL
TTA	NULL
AAT	NULL
TCT	NULL
TCC	NULL
GTT	NULL
CAG	NULL
AGT	NULL
ATT	NULL
AGG	NULL
E	NULL
G	NULL
E	NULL
o	NULL
R	NULL
T	NULL
$	NULL
D	NULL
E	NULL
T	NULL
L	NULL
N	NULL
$	NULL
S	NULL
v	NULL
o	NULL
$	NULL
I	NULL
R	NULL
ACT	NULL
ATA	NULL
CAG	NULL
GCT	NULL
CCA	NULL
ACC	NULL
CAA	NULL
GTT	NULL
CCA	NULL
GTG	NULL
GTT	NULL
GTG	NULL
TCT	NULL
CCT	NULL
AGG	NULL
AAT	NULL
CAG	NULL
CAG	NULL
TTG	NULL
CAT	NULL
ACA	NULL
GTA	NULL
ACA	NULL
CTC	NULL
CAA	NULL
T	NULL
I	NULL
a	NULL
A	NULL
P	NULL
T	NULL
o	NULL
v	NULL
P	NULL
vo	NULL
v	NULL
ov	NULL
E	NULL
P	NULL
R	NULL
N	NULL
o	NULL
o	NULL
L	NULL
H	NULL
T	NULL
v	NULL
T	NULL
L	NULL
a	NULL
ACA	NULL
GTG	NULL
CCA	NULL
CTC	NULL
ACA	NULL
ACA	NULL
GTT	NULL
ATA	NULL
GCC	NULL
AGC	NULL
ACA	NULL
GAT	NULL
CCA	NULL
TCA	NULL
GCA	NULL
GGT	NULL
ACT	NULL
GGA	NULL
TCT	NULL
CAG	NULL
AAG	NULL
TTT	NULL
ATT	NULL
TTA	NULL
CAA	NULL
T	NULL
v	NULL
P	NULL
L	NULL
T	NULL
T	NULL
v	NULL
I	NULL
A	NULL
S	NULL
T	NULL
D	NULL
P	NULL
S	NULL
A	NULL
G	NULL
T	NULL
G	NULL
S	NULL
o	NULL
K	NULL
F	NULL
I	NULL
L	NULL
a	NULL
GCC	NULL
ATT	NULL
CCA	NULL
TCA	NULL
TCA	NULL
CAG	NULL
CCC	NULL
ATG	NULL
ACA	NULL
GTA	NULL
CTG	NULL
AAA	NULL
GAA	NULL
AAT	NULL
GTC	NULL
ATG	NULL
CTG	NULL
CAG	NULL
TCA	NULL
CAA	NULL
AAG	NULL
GCG	NULL
GGC	NULL
TCT	NULL
CCT	NULL
A	NULL
I	NULL
P	NULL
S	NULL
S	NULL
a	NULL
P	NULL
M	NULL
T	NULL
v	NULL
L	NULL
K	NULL
E	NULL
N	NULL
v	NULL
H	NULL
Lo	NULL
0	NULL
§	NULL
a	NULL
K	NULL
A	NULL
G	NULL
S	NULL
P	NULL
CCT	NULL
TCA	NULL
ATT	NULL
GTC	NULL
TTG	NULL
GGC	NULL
CCT	NULL
GCC	NULL
CAG	NULL
GTT	NULL
CAG	NULL
CAG	NULL
GTC	NULL
CTT	NULL
ACT	NULL
AGC	NULL
AAT	NULL
GTT	NULL
CAG	NULL
ACC	NULL
ATT	NULL
TGC	NULL
AAT	NULL
GGA	NULL
ACC	NULL
P	NULL
S	NULL
I	NULL
v	NULL
L	NULL
G	NULL
P	NULL
A	NULL
go	NULL
v	NULL
ge	NULL
e	NULL
v	NULL
L	NULL
T	NULL
$	NULL
N	NULL
v	NULL
a	NULL
T	NULL
I	NULL
C	NULL
N	NULL
G	NULL
T	NULL
GTC	NULL
AGT	NULL
GTG	NULL
GCT	NULL
TCC	NULL
TCT	NULL
CCA	NULL
TCC	NULL
TTC	NULL
AGT	NULL
GCT	NULL
ACT	NULL
GCA	NULL
CCT	NULL
GGG	NULL
GTG	NULL
ACC	NULL
TIT	NULL
TCT	NULL
CCT	NULL
CGC	NULL
AGT	NULL
TCA	NULL
CAG	NULL
CTG	NULL
v	NULL
S	NULL
v	NULL
A	NULL
$	NULL
S	NULL
P	NULL
S	NULL
F	NULL
S	NULL
A	NULL
T	NULL
A	NULL
P	NULL
vo	NULL
v	NULL
T	NULL
F	NULL
S	NULL
P	NULL
R	NULL
S	NULL
S	NULL
o	NULL
L	NULL
GTT	NULL
GCT	NULL
CAC	NULL
CCA	NULL
CCT	NULL
GGC	NULL
ACT	NULL
GTA	NULL
ATC	NULL
ACT	NULL
TCA	NULL
GTT	NULL
ATC	NULL
AAA	NULL
ACT	NULL
CAA	NULL
GAA	NULL
ACA	NULL
AAA	NULL
ACT	NULL
CTT	NULL
ACA	NULL
CAG	NULL
GAA	NULL
GTA	NULL
v	NULL
H	NULL
P	NULL
P	NULL
G	NULL
T	NULL
v	NULL
I	NULL
T	NULL
8	NULL
v	NULL
I	NULL
K	NULL
a	NULL
E	NULL
T	NULL
K	NULL
T	NULL
L	NULL
T	NULL
o	NULL
E	NULL
v	NULL
A	NULL
T	NULL
GAG	NULL
AAA	NULL
AAG	NULL
GAA	NULL
TCT	NULL
GAA	NULL
GAT	NULL
CAT	NULL
TTG	NULL
AAA	NULL
GAG	NULL
AAC	NULL
ACT	NULL
GAG	NULL
AAA	NULL
ACG	NULL
GAG	NULL
CAG	NULL
CAG	NULL
CCA	NULL
CAG	NULL
CCT	NULL
TAT	NULL
GTG	NULL
ATG	NULL
E	NULL
K	NULL
K	NULL
E	NULL
S	NULL
E	NULL
D	NULL
A	NULL
L	NULL
K	NULL
E	NULL
N	NULL
T	NULL
E	NULL
K	NULL
T	NULL
E	NULL
o	NULL
a	NULL
H	NULL
o	NULL
P	NULL
Y	NULL
v	NULL
-	NULL
M	NULL
GTA	NULL
GTG	NULL
TCC	NULL
AGT	NULL
TCC	NULL
AAT	NULL
GGA	NULL
TTT	NULL
ACT	NULL
TCT	NULL
CAG	NULL
GTA	NULL
GCT	NULL
ATG	NULL
AAA	NULL
CAA	NULL
AAC	NULL
GAA	NULL
CTG	NULL
CTG	NULL
GAA	NULL
CCC	NULL
AAC	NULL
TCT	NULL
TIT	NULL
v	NULL
v	NULL
S	NULL
S	NULL
5	NULL
N	NULL
G	NULL
F	NULL
T	NULL
$	NULL
o	NULL
v	NULL
A	NULL
M	NULL
K	NULL
Q	NULL
N	NULL
E	NULL
L	NULL
L	NULL
E	NULL
P	NULL
N	NULL
5	NULL
F	NULL
TQG	NULL
TTAATATACCAAAGCTTATGAATAATTGTTTGTTAATTGAACATTTTCAATTATATGCAGACTGACTGATTCTAAGATAAATTCTAAGGAGGTTT	NULL
CTAATTTGTAATTGTTAAAAATAGAGTTAATTTTGACTTTGTTAGATGAGGGAGGAAAAC	NULL
...	NULL
1209	NULL
bp	NULL
...	NULL
TATTATTAAATAAATCATATAAAAAA	NULL
100	NULL
200	NULL
300	NULL
381	NULL
9	NULL
456	NULL
44	NULL
531	NULL
69	NULL
3576	NULL
J.	NULL
Viror	NULL
.	NULL

FIG	NULL
.	NULL

3	NULL
.	NULL

Nucleotide	NULL
and	NULL
predicted	NULL
amino	NULL
acid	NULL
sequences	NULL
of	NULL
the	NULL
full-length	NULL
human	NULL
Elf-1	NULL
cDNA	NULL
.	NULL

The	NULL
acidic	NULL
region	NULL
is	NULL
denoted	NULL
by	NULL
the	NULL
bold	NULL
underline	NULL
.	NULL

The	NULL
conserved	NULL
a-helical	NULL
region	NULL
of	NULL
the	NULL
DNA-binding	NULL
domain	NULL
is	NULL
denoted	NULL
by	NULL
the	NULL
double	NULL
underline	NULL
.	NULL

The	NULL
basic	NULL
region	NULL
of	NULL
the	NULL
DNA-binding	NULL
domain	NULL
is	NULL
denoted	NULL
by	NULL
the	NULL
single	NULL
underline	NULL
.	NULL

The	NULL
serine-threonine-rich	NULL
region	NULL
immediately	NULL
COOH	NULL
terminal	NULL
to	NULL
the	NULL
DNA-binding	NULL
domain	NULL
is	NULL
boxed	NULL
.	NULL

The	NULL
polyadenylation	NULL
signal	NULL
is	NULL
overlined	NULL
.	NULL

Nucleotide	NULL
and	NULL
amino	NULL
acid	NULL
numbers	NULL
are	NULL
shown	NULL
at	NULL
the	NULL
right	NULL
.	NULL

The	NULL
315-bp	NULL
5°	NULL
untranslated	NULL
region	NULL
begins	NULL
at	NULL
the	NULL
arrow	NULL
.	NULL

Only	NULL
a	NULL
part	NULL
of	NULL
the	NULL
1,392-bp	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
is	NULL
shown	NULL
.	NULL

cated	NULL
by	NULL
simple	NULL
overexpression	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
cooperative	NULL
interactions	NULL
between	NULL
Ets	NULL
family	NULL
members	NULL
and	NULL
other	NULL
transcription	NULL
factors	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
fully	NULL
defined	NULL
.	NULL

However	NULL
,	NULL
structural	NULL
comparisons	NULL
of	NULL
the	NULL
different	NULL
Ets	NULL
family	NULL
members	NULL
and	NULL
their	NULL
cooperative	NULL
partners	NULL
suggest	NULL
that	NULL
multiple	NULL
distinct	NULL
interactive	NULL
domains	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
this	NULL
cooperativity	NULL
(	NULL
15	NULL
,	NULL
28	NULL
,	NULL
37	NULL
)	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
also	NULL
suggest	NULL
that	NULL
different	NULL
Ets	NULL
family	NULL
members	NULL
display	NULL
distinct	NULL
DNA-binding	NULL
specificities	NULL
and	NULL
may	NULL
thereby	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
Vor	NULL
.	NULL

66	NULL
,	NULL
1992	NULL
Elf-1	NULL
BINDS	NULL
REGULATORY	NULL
MOTIFS	NULL
IN	NULL
HIV-2	NULL
LTR	NULL
5895	NULL
o	NULL
9	NULL
A	NULL
.	NULL

B.	NULL
eral	NULL
Total	NULL
C	NULL
:	NULL
«	NULL
E	NULL
A	NULL
a	NULL
N	NULL
=	NULL
E2	NULL
a	NULL
I	NULL
u	NULL
o	NULL
G	NULL
G	NULL
<	NULL
u	NULL
p	NULL
4	NULL
J	NULL
<	NULL
T	NULL
:	NULL
+	NULL
:	NULL
=	NULL
+	NULL
Ab	NULL
|	NULL
_s	NULL
£	NULL
8	NULL
s	NULL
8	NULL
|-	NULL
B	NULL
&	NULL
8	NULL
#	NULL
&	NULL
Competitor	NULL
:	NULL
-	NULL
PuB2	NULL
APuB2	NULL
_PuBi	NULL
APuB1	NULL
9	NULL
W	NULL
2	NULL
«	NULL
moar	NULL
ar	NULL
a	NULL
Protein	NULL
dj	NULL
in	NULL
d	NULL
i	NULL
Protein	NULL
:	NULL
_	NULL
|	NULL
Elf-1	NULL
Nuclear	NULL
Extract	NULL
ng	NULL
:	NULL
10	NULL
20	NULL
10	NULL
20	NULL
10	NULL
50100	NULL
10	NULL
50	NULL
100	NULL
Elf-1	NULL
-	NULL
»	NULL
.	NULL

we	NULL
-	NULL
»	NULL
©	NULL
W.	NULL
Wel	NULL
-	NULL
»	NULL
p	NULL
leg	NULL
tn	NULL
bs	NULL
tag	NULL
was	NULL
bo	NULL
800	NULL
ideas	NULL
WOOABGGA	NULL
|	NULL
Wikwwi	NULL
(	NULL
l	NULL
wo	NULL
»	NULL
ttt	NULL
wns	NULL
l	NULL
=	NULL
|=	NULL
ims	NULL
<	NULL
=	NULL
Ets-1-	NULL
»	NULL
-	NULL
46	NULL
aks	NULL
S9	NULL
pusess	NULL
To2	NULL
PuBi	NULL
PuB2	NULL
PuB2	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Binding	NULL
of	NULL
Elf-1	NULL
to	NULL
purine	NULL
boxes	NULL
in	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Binding	NULL
of	NULL
in	NULL
vitro-transcribed	NULL
and	NULL
-translated	NULL
Elf-1	NULL
and	NULL
Ets-1	NULL
proteins	NULL
to	NULL
radiolabeled	NULL
PuB1	NULL
and	NULL
Ta	NULL
?	NULL

(	NULL
22	NULL
)	NULL
probes	NULL
was	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
40	NULL
,	NULL
45	NULL
)	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
Elf-1	NULL
and	NULL
Ets-1	NULL
bands	NULL
are	NULL
shown	NULL
by	NULL
arrows	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Antibody	NULL
blocking	NULL
of	NULL
Elf-1	NULL
binding	NULL
.	NULL

Binding	NULL
reaction	NULL
mixtures	NULL
containing	NULL
in	NULL
vitro-transcribed	NULL
and	NULL
translated	NULL
Elf-1	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
or	NULL
nuclear	NULL
extracts	NULL
from	NULL
PMA-ionomycin-activated	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
1	NULL
pl	NULL
of	NULL
preimmune	NULL
or	NULL
«	NULL
-Elf-1	NULL
rabbit	NULL
antiserum	NULL
or	NULL
1	NULL
pl	NULL
of	NULL
the	NULL
previously	NULL
described	NULL
a-Ets-1	NULL
(	NULL
22	NULL
)	NULL
,	NULL
«	NULL
-Ets-2	NULL
(	NULL
14	NULL
)	NULL
,	NULL
or	NULL
a	NULL
commercially	NULL
available	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
Calif.	NULL
)	NULL
«	NULL
-IL-2	NULL
receptor	NULL
(	NULL
«	NULL
-IL-2R	NULL
)	NULL
MAb	NULL
at	NULL
4°C	NULL
for	NULL
15	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
radiolabeled	NULL
PuB2	NULL
probe	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
Elf-1	NULL
band	NULL
is	NULL
indicated	NULL
with	NULL
an	NULL
arrow	NULL
.	NULL

The	NULL
faint	NULL
band	NULL
remaining	NULL
in	NULL
the	NULL
nuclear	NULL
extract	NULL
lane	NULL
following	NULL
pretreatment	NULL
with	NULL
the	NULL
o-Elf-1	NULL
antiserum	NULL
and	NULL
competitions	NULL
with	NULL
PuBl	NULL
and	NULL
PuB2	NULL
oligonucleotides	NULL
represents	NULL
a	NULL
nonspecific	NULL
DNA-binding	NULL
activity	NULL
with	NULL
slightly	NULL
faster	NULL
mobility	NULL
than	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
Elf-1	NULL
protein	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Cold	NULL
competitor	NULL
experiments	NULL
.	NULL

Radiolabeled	NULL
PuB2	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
PMA-ionomycin-activated	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
unlabeled	NULL
competitor	NULL
oligonucleotides	NULL
.	NULL

The	NULL
nucleotide	NULL
substitutions	NULL
used	NULL
to	NULL
make	NULL
the	NULL
mutant	NULL
PuB1	NULL
(	NULL
APuB1	NULL
)	NULL
and	NULL
PuB2	NULL
(	NULL
APuB2	NULL
)	NULL
oligonucleotides	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
.	NULL

The	NULL
Elf-1	NULL
band	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
arrow	NULL
.	NULL

The	NULL
two	NULL
lower	NULL
bands	NULL
represent	NULL
non-sequence-specific	NULL
DNA-binding	NULL
activities	NULL
in	NULL
that	NULL
they	NULL
are	NULL
inhibited	NULL
equally	NULL
by	NULL
wild-type	NULL
and	NULL
mutant	NULL
PuBl	NULL
and	NULL
PuB2	NULL
cold	NULL
competitor	NULL
oligonucleotides	NULL
as	NULL
well	NULL
as	NULL
by	NULL
several	NULL
unrelated	NULL
oligonucleotide	NULL
competitors	NULL
.	NULL

different	NULL
sets	NULL
of	NULL
genes	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
for	NULL
example	NULL
,	NULL
Ets-1	NULL
binds	NULL
to	NULL
the	NULL
TCR	NULL
a	NULL
enhancer	NULL
but	NULL
fails	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

Conversely	NULL
,	NULL
Elf-1	NULL
binds	NULL
to	NULL
the	NULL
HIV-2	NULL
but	NULL
not	NULL
to	NULL
the	NULL
TCR	NULL
a	NULL
enhancer	NULL
.	NULL

Furthermore	NULL
,	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
multiple	NULL
Ets	NULL
family	NULL
members	NULL
are	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
40	NULL
)	NULL
,	NULL
EIf-1	NULL
is	NULL
the	NULL
only	NULL
protein	NULL
in	NULL
activated	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
that	NULL
can	NULL
be	NULL
shown	NULL
by	NULL
EMSA	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
purine	NULL
boxes	NULL
in	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
.	NULL

Thus	NULL
,	NULL
transcription	NULL
factors	NULL
containing	NULL
Ets	NULL
domains	NULL
appear	NULL
to	NULL
display	NULL
pleiomorphic	NULL
regulatory	NULL
activities	NULL
by	NULL
virtue	NULL
of	NULL
their	NULL
abilities	NULL
to	NULL
cooperate	NULL
with	NULL
multiple	NULL
other	NULL
DNA-binding	NULL
proteins	NULL
and	NULL
to	NULL
bind	NULL
with	NULL
different	NULL
specificities	NULL
to	NULL
purine-rich	NULL
enhancer	NULL
motifs	NULL
.	NULL

In	NULL
a	NULL
separate	NULL
report	NULL
,	NULL
we	NULL
have	NULL
recently	NULL
demonstrated	NULL
that	NULL
nucleotides	NULL
at	NULL
the	NULL
3	NULL
'	NULL
ends	NULL
of	NULL
the	NULL
Ets	NULL
binding	NULL
sites	NULL
determine	NULL
the	NULL
fine	NULL
specificities	NULL
of	NULL
binding	NULL
of	NULL
Ets-l1	NULL
and	NULL
Elf-1	NULL
to	NULL
naturally	NULL
occurring	NULL
Ets	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
TCR	NULL
«	NULL
,	NULL
IL-2	NULL
,	NULL
and	NULL
HIV-2	NULL
enhancers	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
additional	NULL
Ets	NULL
or	NULL
non-Ets	NULL
transcription	NULL
factors	NULL
bind	NULL
to	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
in	NULL
vivo	NULL
but	NULL
fail	NULL
to	NULL
bind	NULL
in	NULL
in	NULL
vitro	NULL
EMSAs	NULL
.	NULL

Although	NULL
the	NULL
organization	NULL
of	NULL
HIV-2	NULL
is	NULL
quite	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
HIV-1	NULL
,	NULL
the	NULL
nucleotide	NULL
sequences	NULL
of	NULL
the	NULL
two	NULL
viruses	NULL
differ	NULL
significantly	NULL
(	NULL
19	NULL
)	NULL
.	NULL

This	NULL
sequence	NULL
divergence	NULL
involves	NULL
both	NULL
the	NULL
structural	NULL
genes	NULL
of	NULL
the	NULL
viruses	NULL
and	NULL
their	NULL
transcriptional	NULL
enhancers	NULL
.	NULL

These	NULL
differences	NULL
in	NULL
primary	NULL
structure	NULL
are	NULL
reflected	NULL
in	NULL
the	NULL
distinct	NULL
immunodeficiency	NULL
syndromes	NULL
caused	NULL
by	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
the	NULL
asymptomatic	NULL
latent	NULL
period	NULL
of	NULL
HIV-2	NULL
infection	NULL
appears	NULL
to	NULL
be	NULL
significantly	NULL
longer	NULL
than	NULL
that	NULL
associated	NULL
with	NULL
HIV-1	NULL
infection	NULL
(	NULL
4	NULL
,	NULL
25	NULL
)	NULL
.	NULL

The	NULL
studies	NULL
described	NULL
in	NULL
this	NULL
report	NULL
suggest	NULL
a	NULL
molecular	NULL
mechanism	NULL
that	NULL
may	NULL
account	NULL
for	NULL
these	NULL
differences	NULL
.	NULL

Unlike	NULL
HIV-1	NULL
trans	NULL
activation	NULL
,	NULL
which	NULL
appears	NULL
to	NULL
require	NULL
only	NULL
NF-	NULL
«	NULL
B	NULL
for	NULL
induction	NULL
from	NULL
latency	NULL
(	NULL
30	NULL
,	NULL
36	NULL
)	NULL
,	NULL
HIV-2	NULL
trans	NULL
activation	NULL
requires	NULL
both	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Elf-1	NULL
,	NULL
a	NULL
novel	NULL
Ets-related	NULL
family	NULL
member	NULL
present	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
,	NULL
as	NULL
is	NULL
the	NULL
case	NULL
for	NULL
avian	NULL
and	NULL
murine	NULL
retroviruses	NULL
,	NULL
human	NULL
retroviruses	NULL
have	NULL
evolved	NULL
to	NULL
utilize	NULL
different	NULL
sets	NULL
of	NULL
host	NULL
factors	NULL
for	NULL
transcriptional	NULL
regulation	NULL
.	NULL

These	NULL
results	NULL
also	NULL
suggest	NULL
Elf-1	NULL
as	NULL
a	NULL
potential	NULL
target	NULL
for	NULL
therapeutic	NULL
approaches	NULL
designed	NULL
to	NULL
block	NULL
the	NULL
activation	NULL
of	NULL
HIV-2	NULL
from	NULL
latency	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
David	NULL
Ginsburg	NULL
for	NULL
helpful	NULL
comments	NULL
on	NULL
the	NULL
manu-script	NULL
,	NULL
William	NULL
Studier	NULL
for	NULL
the	NULL
pET-3b	NULL
expression	NULL
vector	NULL
,	NULL
and	NULL
Takis	NULL
Papas	NULL
for	NULL
the	NULL
«	NULL
-Ets-1	NULL
and	NULL
«	NULL
-Ets-2	NULL
MAbs	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
grant	NULL
AI-29673	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
to	NULL
J.M.L	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Arya	NULL
,	NULL
S.	NULL
K.	NULL
1988	NULL
.	NULL

Human	NULL
and	NULL
simian	NULL
immunodeficiency	NULL
retro-viruses	NULL
:	NULL
activation	NULL
and	NULL
differential	NULL
transactivation	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
4:175-186	NULL
.	NULL

2	NULL
.	NULL

Arya	NULL
,	NULL
S.	NULL
K.	NULL
1990	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type-2	NULL
gene	NULL
expression	NULL
:	NULL
two	NULL
enhancers	NULL
and	NULL
their	NULL
activation	NULL
by	NULL
T-cell	NULL
activa-tors	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

2:57-65	NULL
.	NULL

3	NULL
.	NULL

Arya	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1988	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
long	NULL
terminal	NULL
repeat	NULL
:	NULL
analysis	NULL
of	NULL
regulatory	NULL
elements	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:9753-9757	NULL
.	NULL

4	NULL
.	NULL

Barabe	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
P.	NULL
Digoutte	NULL
,	NULL
J.	NULL
F.	NULL
Tristan	NULL
,	NULL
M.	NULL
Peghini	NULL
,	NULL
P.	NULL
Griffet	NULL
,	NULL
P.	NULL
Jean	NULL
,	NULL
P.	NULL
Seignot	NULL
,	NULL
J.	NULL
L.	NULL
Sarthou	NULL
,	NULL
B.	NULL
Leguenno	NULL
,	NULL
C.	NULL
Berlioz	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1988	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
infections	NULL
(	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
)	NULL
in	NULL
Dakar	NULL
.	NULL

Epidemiologic	NULL
and	NULL
clinical	NULL
aspects	NULL
.	NULL

Med	NULL
.	NULL

Trop	NULL
.	NULL

48:337-344	NULL
.	NULL

5	NULL
.	NULL

Bhat	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
K.	NULL
L.	NULL
Komschlies	NULL
,	NULL
S.	NULL
Fujiwara	NULL
,	NULL
R.	NULL
J.	NULL
Fisher	NULL
,	NULL
B.	NULL
J.	NULL
Mathieson	NULL
,	NULL
T.	NULL
A.	NULL
Gregorio	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

Young	NULL
,	NULL
J.	NULL
W.	NULL
Kasik	NULL
,	NULL
K.	NULL
Ozato	NULL
,	NULL
and	NULL
T.	NULL
S.	NULL
Papas	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
of	NULL
ets	NULL
genes	NULL
in	NULL
mouse	NULL
thymocyte	NULL
subsets	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:672-678	NULL
.	NULL

5896	NULL
6	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

LEIDEN	NULL
ET	NULL
AL	NULL
.	NULL

Bosselut	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
F.	NULL
Duvall	NULL
,	NULL
A.	NULL
Gegonne	NULL
,	NULL
M.	NULL
Bailly	NULL
,	NULL
A.	NULL
Hemar	NULL
,	NULL
J.	NULL
Brady	NULL
,	NULL
and	NULL
J.	NULL
Ghysdael	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
product	NULL
of	NULL
the	NULL
c-ets-1	NULL
proto-oncogene	NULL
and	NULL
the	NULL
related	NULL
Ets2	NULL
protein	NULL
act	NULL
as	NULL
transcriptional	NULL
activators	NULL
of	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
HTLV-1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:3137-3144.	NULL
.	NULL

Burtis	NULL
,	NULL
K.	NULL
C.	NULL
,	NULL
C.	NULL
S.	NULL
Thummel	NULL
,	NULL
C.	NULL
W.	NULL
Jones	NULL
,	NULL
F.	NULL
D.	NULL
Karim	NULL
,	NULL
and	NULL
D.	NULL
S.	NULL
Hogness	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Drosophila	NULL
74EF	NULL
early	NULL
puff	NULL
contains	NULL
E74	NULL
,	NULL
a	NULL
complex	NULL
ecdysone-inducible	NULL
gene	NULL
that	NULL
encodes	NULL
two	NULL
ets-related	NULL
proteins	NULL
.	NULL

Cell	NULL
61:85-99.	NULL
.	NULL

Clavel	NULL
,	NULL
F.	NULL
,	NULL
D.	NULL
Guetard	NULL
,	NULL
F.	NULL
Brun-Vezinet	NULL
,	NULL
S.	NULL
Chamaret	NULL
,	NULL
M.	NULL
A.	NULL
Rey	NULL
,	NULL
M.	NULL
O.	NULL
Santos-Ferreira	NULL
,	NULL
A.	NULL
G.	NULL
Laurent	NULL
,	NULL
C.	NULL
Dauguet	NULL
,	NULL
C.	NULL
Katlama	NULL
,	NULL
C.	NULL
Rouzioux	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1986	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
new	NULL
human	NULL
retrovirus	NULL
from	NULL
West	NULL
African	NULL
patients	NULL
with	NULL
AIDS	NULL
.	NULL

Science	NULL
233:343-346.	NULL
.	NULL

Clavel	NULL
,	NULL
F.	NULL
,	NULL
M.	NULL
Guyader	NULL
,	NULL
D.	NULL
Guetard	NULL
,	NULL
M.	NULL
Salle	NULL
,	NULL
L.	NULL
Montagnier	NULL
,	NULL
and	NULL
M.	NULL
Alizon	NULL
.	NULL

1986	NULL
.	NULL

Molecular	NULL
cloning	NULL
and	NULL
polymorphism	NULL
of	NULL
the	NULL
human	NULL
immune	NULL
deficiency	NULL
virus	NULL
type	NULL
2	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
324:691-695	NULL
.	NULL

Clavel	NULL
,	NULL
F.	NULL
,	NULL
K.	NULL
Mansinho	NULL
,	NULL
S.	NULL
Chamaret	NULL
,	NULL
D.	NULL
Guetard	NULL
,	NULL
V.	NULL
Favier	NULL
,	NULL
J.	NULL
Nina	NULL
,	NULL
M.	NULL
O.	NULL
Santos-Ferreira	NULL
,	NULL
J.	NULL
L.	NULL
Champalimaud	NULL
,	NULL
and	NULL
L.	NULL
Montagnier	NULL
.	NULL

1987	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
infection	NULL
associated	NULL
with	NULL
AIDS	NULL
in	NULL
West	NULL
Africa	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

316:1180-1185	NULL
.	NULL

Cortes	NULL
,	NULL
E.	NULL
,	NULL
R.	NULL
Detels	NULL
,	NULL
D.	NULL
Aboulafia	NULL
,	NULL
X.	NULL
L.	NULL
Li	NULL
,	NULL
T.	NULL
Moudgil	NULL
,	NULL
M.	NULL
Alam	NULL
,	NULL
C.	NULL
Bonecker	NULL
,	NULL
A.	NULL
Gonzaga	NULL
,	NULL
L.	NULL
Oyafuso	NULL
,	NULL
and	NULL
M.	NULL
Tondo	NULL
.	NULL

1989	NULL
.	NULL

HIV-1	NULL
,	NULL
HIV-2	NULL
,	NULL
and	NULL
HTLV-I	NULL
infection	NULL
in	NULL
high-risk	NULL
groups	NULL
in	NULL
Brazil	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

320:953-958	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
J.-P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Belagaje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715-1724	NULL
.	NULL

Emerman	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Guyader	NULL
,	NULL
L.	NULL
Montagnier	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Muesing	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
transactivator	NULL
is	NULL
different	NULL
from	NULL
that	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:3755-3760	NULL
.	NULL

Fujiwara	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
J.	NULL
Fisher	NULL
,	NULL
N.	NULL
K.	NULL
Bhat	NULL
,	NULL
S.	NULL
M.	NULL
Diaz	NULL
de	NULL
la	NULL
Espina	NULL
,	NULL
and	NULL
T.	NULL
S.	NULL
Papas	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
short-lived	NULL
nuclear	NULL
phosphoprotein	NULL
encoded	NULL
by	NULL
the	NULL
human	NULL
ets-2	NULL
proto-oncogene	NULL
is	NULL
stabilized	NULL
by	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C.	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:4700-4706	NULL
.	NULL

Fujiwara	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Koizumi	NULL
,	NULL
R.	NULL
J.	NULL
Fisher	NULL
,	NULL
N.	NULL
K.	NULL
Bhat	NULL
,	NULL
and	NULL
T.	NULL
S.	NULL
Papas	NULL
.	NULL

1990	NULL
.	NULL

Phosphorylation	NULL
of	NULL
the	NULL
ETS-2	NULL
protein	NULL
:	NULL
regulation	NULL
by	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor-CD3	NULL
complex	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:1249-1253	NULL
.	NULL

Gottschalk	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
receptor	NULL
B	NULL
gene	NULL
transcriptional	NULL
enhancer	NULL
:	NULL
common	NULL
nuclear	NULL
proteins	NULL
interact	NULL
with	NULL
the	NULL
transcriptional	NULL
regulatory	NULL
elements	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
a	NULL
and	NULL
B	NULL
genes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:5486-5495	NULL
.	NULL

Greene	NULL
,	NULL
W.	NULL
C.	NULL
1991	NULL
.	NULL

The	NULL
molecular	NULL
biology	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

324:308-317	NULL
.	NULL

Gunther	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Nye	NULL
,	NULL
R.	NULL
S.	NULL
Bryner	NULL
,	NULL
and	NULL
B.	NULL
J.	NULL
Graves	NULL
.	NULL

1990	NULL
.	NULL

Sequence-specific	NULL
DNA	NULL
binding	NULL
of	NULL
the	NULL
proto-oncoprotein	NULL
ets-1	NULL
defines	NULL
a	NULL
transcriptional	NULL
activator	NULL
sequence	NULL
within	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
the	NULL
Moloney	NULL
murine	NULL
sarcoma	NULL
virus	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:667-679	NULL
.	NULL

Guyader	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Emerman	NULL
,	NULL
P.	NULL
Sonigo	NULL
,	NULL
F.	NULL
Clavel	NULL
,	NULL
L.	NULL
Montagnier	NULL
,	NULL
and	NULL
M.	NULL
Alizon	NULL
.	NULL

1987	NULL
.	NULL

Genome	NULL
organization	NULL
and	NULL
transactivation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:662-669	NULL
.	NULL

Ho	NULL
,	NULL
I.-C.	NULL
,	NULL
N.	NULL
K.	NULL
Bhat	NULL
,	NULL
L.	NULL
R.	NULL
Gottschalk	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
T.	NULL
S.	NULL
Papas	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1990	NULL
.	NULL

Sequence-specific	NULL
binding	NULL
of	NULL
human	NULL
ets-1	NULL
to	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
a	NULL
gene	NULL
enhancer	NULL
.	NULL

Science	NULL
250:814-818	NULL
.	NULL

Ho	NULL
,	NULL
I.-C.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1990	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
receptor	NULL
a	NULL
gene	NULL
enhancer	NULL
:	NULL
multiple	NULL
ubiquitous	NULL
and	NULL
T-cell	NULL
specific	NULL
nuclear	NULL
proteins	NULL
interact	NULL
with	NULL
four	NULL
hypomethylated	NULL
enhancer	NULL
elements	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:4720-4727	NULL
.	NULL

Ho	NULL
,	NULL
I.-C.	NULL
,	NULL
L.-H.	NULL
Yang	NULL
,	NULL
G.	NULL
Morie	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
T-cell-specific	NULL
transcriptional	NULL
enhancer	NULL
element	NULL
3	NULL
'	NULL
of	NULL
Ca	NULL
in	NULL
the	NULL
human	NULL
T-cell	NULL
receptor	NULL
a	NULL
locus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:6714-6718	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

1989	NULL
.	NULL

HIV	NULL
trans-activation	NULL
and	NULL
transcription	NULL
con	NULL
24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

trol	NULL
mechanisms	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

1:127-135	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
,	NULL
M.	NULL
M.	NULL
Gillespie	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1987	NULL
.	NULL

T-cell	NULL
proliferation	NULL
involving	NULL
the	NULL
CD28	NULL
pathway	NULL
is	NULL
associated	NULL
with	NULL
cyclosporine-resistant	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:4472-4481	NULL
.	NULL

Kanki	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

1989	NULL
.	NULL

Clinical	NULL
significance	NULL
of	NULL
HIV-2	NULL
infection	NULL
in	NULL
West	NULL
Africa	NULL
,	NULL
p.	NULL
95-108	NULL
.	NULL

In	NULL
P.	NULL
Volberding	NULL
and	NULL
M.	NULL
A.	NULL
Jacobson	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
AIDS	NULL
clinical	NULL
reviews	NULL
.	NULL

Marcel	NULL
Dekker	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Karim	NULL
,	NULL
F.	NULL
D.	NULL
,	NULL
L.	NULL
D.	NULL
Urness	NULL
,	NULL
C.	NULL
S.	NULL
Thummel	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
C.	NULL
V.	NULL
Gunther	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Nye	NULL
,	NULL
and	NULL
B.	NULL
J.	NULL
Graves	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
ETS-domain	NULL
:	NULL
a	NULL
new	NULL
DNA-binding	NULL
motif	NULL
that	NULL
recognizes	NULL
a	NULL
purine-rich	NULL
core	NULL
DNA	NULL
sequence	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:1451-1453	NULL
.	NULL

Klemsz	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Maki	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
macrophage	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
related	NULL
to	NULL
the	NULL
ets	NULL
oncogene	NULL
.	NULL

Cell	NULL
61:113-124	NULL
.	NULL

Koizumi	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
J.	NULL
Fisher	NULL
,	NULL
S.	NULL
Fujiwara	NULL
,	NULL
C.	NULL
Jorcyk	NULL
,	NULL
N.	NULL
K.	NULL
Bhat	NULL
,	NULL
A.	NULL
Seth	NULL
,	NULL
and	NULL
T.	NULL
S.	NULL
Papas	NULL
.	NULL

1990	NULL
.	NULL

Isoforms	NULL
of	NULL
the	NULL
human	NULL
ets-l	NULL
protein	NULL
:	NULL
generation	NULL
by	NULL
alternative	NULL
splicing	NULL
and	NULL
differential	NULL
phos-phorylation	NULL
.	NULL

Oncogene	NULL
5:675-681	NULL
.	NULL

Maekawa	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Sakura	NULL
,	NULL
C.	NULL
Kanei-Ishii	NULL
,	NULL
T.	NULL
Sudo	NULL
,	NULL
T.	NULL
Yoshimura	NULL
,	NULL
J.	NULL
Fujisawa	NULL
,	NULL
M.	NULL
Yoshida	NULL
,	NULL
and	NULL
S.	NULL
Ishii	NULL
.	NULL

1989	NULL
.	NULL

Leucine	NULL
zipper	NULL
structure	NULL
of	NULL
the	NULL
protein	NULL
CRE-BP1	NULL
binding	NULL
to	NULL
the	NULL
cyclic	NULL
AMP	NULL
response	NULL
element	NULL
in	NULL
brain	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:2023-2028	NULL
.	NULL

Markovitz	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
Hannibal	NULL
,	NULL
V.	NULL
L.	NULL
Perez	NULL
,	NULL
C.	NULL
Gauntt	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
(	NULL
HIVs	NULL
)	NULL
:	NULL
a	NULL
specific	NULL
regulatory	NULL
element	NULL
in	NULL
HIV-2	NULL
responds	NULL
to	NULL
stimulation	NULL
of	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:9098-9102	NULL
.	NULL

30a	NULL
.	NULL

Markovitz	NULL
,	NULL
D.	NULL
,	NULL
M.	NULL
Smith	NULL
,	NULL
J.	NULL
Helfinger	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
M.	NULL
Hanni-	NULL
31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42.	NULL
bal	NULL
,	NULL
G.	NULL
Nabel	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

McCune	NULL
,	NULL
J.	NULL
M.	NULL
1991	NULL
.	NULL

HIV-1	NULL
:	NULL
the	NULL
infective	NULL
process	NULL
in	NULL
vivo	NULL
.	NULL

Cell	NULL
64:351-363	NULL
.	NULL

McKnight	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1986	NULL
.	NULL

Transcriptional	NULL
selectivity	NULL
of	NULL
viral	NULL
genes	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Cell	NULL
46:795-805	NULL
.	NULL

Mitchell	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1989	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
in	NULL
mammalian	NULL
cells	NULL
by	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
proteins	NULL
.	NULL

Science	NULL
245:371-378	NULL
.	NULL

Miyatake	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Otsuka	NULL
,	NULL
T.	NULL
Yokota	NULL
,	NULL
F.	NULL
Lee	NULL
,	NULL
and	NULL
K.	NULL
Arai	NULL
.	NULL

1985	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
chromosomal	NULL
gene	NULL
for	NULL
granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
:	NULL
comparison	NULL
of	NULL
the	NULL
mouse	NULL
and	NULL
human	NULL
genes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

4:2561-2568	NULL
.	NULL

Miyatake	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Yokota	NULL
,	NULL
F.	NULL
Lee	NULL
,	NULL
and	NULL
K.	NULL
Arai	NULL
.	NULL

1985	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
chromosomal	NULL
gene	NULL
for	NULL
murine	NULL
interleukin-3	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:316-320	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Pognonec	NULL
,	NULL
P.	NULL
,	NULL
K.	NULL
E.	NULL
Boulukos	NULL
,	NULL
J.	NULL
C.	NULL
Gesquiere	NULL
,	NULL
D.	NULL
Stehelin	NULL
,	NULL
and	NULL
J.	NULL
Ghysdael	NULL
.	NULL

1988	NULL
.	NULL

Mitogenic	NULL
stimulation	NULL
of	NULL
thymocytes	NULL
results	NULL
in	NULL
the	NULL
calcium-dependent	NULL
phosphorylation	NULL
of	NULL
c-ets-1	NULL
proteins	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7:977-983	NULL
.	NULL

Studier	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
A.	NULL
H.	NULL
Rosenberg	NULL
,	NULL
J.	NULL
J.	NULL
Dunn	NULL
,	NULL
and	NULL
J.	NULL
W.	NULL
Dubendorff	NULL
.	NULL

1990	NULL
.	NULL

Use	NULL
of	NULL
T7	NULL
RNA	NULL
polymerase	NULL
to	NULL
direct	NULL
expression	NULL
of	NULL
cloned	NULL
genes	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

185:60-89	NULL
.	NULL

Tan	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Horikoshi	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1989	NULL
.	NULL

Purification	NULL
and	NULL
characterization	NULL
of	NULL
multiple	NULL
nuclear	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
TAX-inducible	NULL
enhancer	NULL
within	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:1733-1745	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
C.-Y	NULL
.	NULL

Wang	NULL
,	NULL
I.-C.	NULL
Ho	NULL
,	NULL
P.	NULL
R.	NULL
Bohjanen	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
S.	NULL
Miesfeldt	NULL
,	NULL
L.	NULL
Zhang	NULL
,	NULL
G.	NULL
J.	NULL
Nabel	NULL
,	NULL
B.	NULL
Karpinski	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1992.	NULL
cis-Acting	NULL
sequences	NULL
required	NULL
for	NULL
inducible	NULL
interleukin-2	NULL
enhancer	NULL
function	NULL
bind	NULL
a	NULL
novel	NULL
Ets-related	NULL
protein	NULL
,	NULL
Elf-1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:1043-1053	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

Brown	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1991	NULL
.	NULL

Convergence	NULL
of	NULL
Ets-	NULL
and	NULL
notch-related	NULL
structural	NULL
motifs	NULL
in	NULL
heteromeric	NULL
DNA	NULL
binding	NULL
complex	NULL
.	NULL

Science	NULL
253:762-768	NULL
.	NULL

Tong-Starkesen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1989	NULL
.	NULL

Signaling	NULL
through	NULL
T	NULL
lymphocyte	NULL
surface	NULL
proteins	NULL
,	NULL
TCR/CD3	NULL
and	NULL
CD28	NULL
,	NULL
activates	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:702-707	NULL
.	NULL

Vor	NULL
.	NULL

66	NULL
,	NULL
1992	NULL
Elf-1	NULL
BINDS	NULL
REGULATORY	NULL
MOTIFS	NULL
IN	NULL
HIV-2	NULL
LTR	NULL
5897	NULL
43	NULL
.	NULL

Turka	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
D.	NULL
G.	NULL
Schatz	NULL
,	NULL
M.	NULL
A.	NULL
Oettinger	NULL
,	NULL
J.	NULL
J.	NULL
Chun	NULL
,	NULL
C.	NULL
Leiden	NULL
.	NULL

1992	NULL
.	NULL

Evolutionary	NULL
conserved	NULL
ets	NULL
family	NULL
members	NULL
display	NULL
Gorka	NULL
,	NULL
K.	NULL
Lee	NULL
,	NULL
W.	NULL
T.	NULL
McCormack	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1991.	NULL
distinct	NULL
DNA	NULL
binding	NULL
specificities	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1391-1399	NULL
.	NULL

Thymocyte	NULL
expression	NULL
of	NULL
RAG-1	NULL
and	NULL
RAG-2	NULL
:	NULL
termination	NULL
by	NULL
T	NULL
45a.W	NULL
C.-Y¥	NULL
.	NULL

,	NULL
C.	NULL
B.	NULL
Th	NULL
B.	NULL
Petryniak	NULL
,	NULL
W.	NULL
G.	NULL
Kaeli	NULL
F	NULL
]	NULL
cell	NULL
receptor	NULL
cross-linking	NULL
.	NULL

Science	NULL
253:778-781.	NULL
a-	NULL
P	NULL
ﬁg	NULL
’	NULL
uid	NULL
en	NULL
.	NULL

Submitt	NULL
Z	NULL
511	NULL
£905	NULL
:	NULL
3:1in	NULL
caeﬁglmak	NULL
,	NULL
em	NULL
,	NULL
an	NULL
44	NULL
.	NULL

Urness	NULL
,	NULL
L.	NULL
D.	NULL
,	NULL
and	NULL
C.	NULL
S.	NULL
Thummel	NULL
.	NULL

1990	NULL
.	NULL

Molecular	NULL
interactions	NULL
,	NULL
within	NULL
the	NULL
ecdysone	NULL
regulatory	NULL
hierarchy	NULL
:	NULL
DNA	NULL
binding	NULL
prop-	NULL
46	NULL
.	NULL

Wasylyk	NULL
,	NULL
.B	NULL
.	NULL

,	NULL
C.	NULL
Wasylyk	NULL
,	NULL
P.	NULL
Flores	NULL
,	NULL
A.	NULL
Begue	NULL
,	NULL
D.	NULL
Leprince	NULL
,	NULL
and	NULL
erties	NULL
of	NULL
the	NULL
Drosophila	NULL
ecdysone-inducible	NULL
E74A	NULL
protein	NULL
.	NULL

Cell	NULL
D.	NULL
Stehelin	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
c-ets	NULL
proto-oncogenes	NULL
encode	NULL
transcrip-63:47-61.	NULL
tion	NULL
factors	NULL
that	NULL
cooperate	NULL
with	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
for	NULL
transcrip-	NULL
45	NULL
.	NULL

Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
B.	NULL
Petryniak	NULL
,	NULL
I.-C.	NULL
Ho	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
tional	NULL
activation	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
346:191-193	NULL
.	NULL

